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ABSTRACT 
SELF-NANOPARTICLE FORMING IMMUNOSTIMULATORY DNA: 
STRUCTURE-FUNCTION RELATIONSHIP STUDIES 
 
Rashad Mammadov 
M.Sc. in Material Science and Nanotechnology 
Supervisor: Assoc. Prof. Dr. Ihsan Gürsel 
January 2009, 107 pages 
 
Toll-like receptors (TLRs) are one the most critical and widely studied 
members of the family of pattern recognition receptors expressed on innate immune 
cells. They recognize microbial signatures, such as bacterial/viral DNA, LPS, from 
gram negative bacteria, peptidoglycan from gram positive bacteria, zymosan from 
yeast, lipopeptides or profilin protein from parasites, and even single or double 
stranded RNA of viruses. Among several members of TLR family, TLR9, that 
recognizes microbial unmethylated dinucleotide motifs on DNA initiate a robust Th1-
biased inflammatory response. Synthetic oligodeoxynucleotides expressing 
unmethylated CpG motifs, mimic bacterial DNA effect and can be harnessed for the 
treatment of health problems ranging from infectious diseases to cancer, or to 
allergy/asthma as well as stand alone immunoprotective agents and also as a vaccine 
adjuvants that improve protection against pathogens. To date, various classes of CpG 
ODNs have been identified and were shown to induce differential immune activation 
in mice and man. Distinct structure-function relationship analyses revealed that these 
single-stranded linear ODNs alter the immune milieu as they are formulated to form 
complex multimeric DNA aggregates. Recently, Guanosine-rich D type CpG ODNs 
has been reported to form complex aggregates, that are differentially regulating 
immune cells to mount an anti-viral immunity. However, the clinical trials of this type 
are hampered mainly due to batch to batch variation during large-scale synthesis. To 
the best of our knowledge, there is no report on self-nanoparticle forming DNA 
except G-rich sequences. This thesis project was designed to generate stable, self-
nanoparticle forming, G-run free, CpG expressing ODNs.  
In this thesis, we designed a new generation CpG ODN, then characterized 
their structural and immunological properties. Our results suggest that dendrimeric 
structure confers higher immunostimulatory potential unparallel to conventional 
ODNs. Following four hours of in vivo ODN administration into mice indicated that 
nanoparticle-forming CpG ODNs initiated substantially high spleen and peritoneal 
exudate cell activation as evidenced by IFNγ and IL-12 production from culture 
medium. In order to shed light on the uptake and binding mechanisms, blocking 
experiments revealed that at least one type of scavenger receptor is critical for 
nanoparticle ODN internalization. Collectively, these data suggested that the 
improved stability to nucleases along with significantly higher binding to immune 
cells (no additional ODN formulation is required) seem to be the critical factors 
contributing to the nanoparticle CpG ODN mediated immune activation. The in vitro 
and in vivo performances implicated that these next generation immune stimulatory 
DNA molecules are promising candidates for various clinical applications.  
 
Keywords: Innate immunity, TLR9, scavenger receptors, nanoparticulate and 
dendrimeric CpG ODN, immunotherapy 
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ÖZET 
KENDĐ KENDĐNE NANOPARÇAÇIK OLUŞTURAN BAĞIŞIKLIK UYARICI 
DNA: YAPI-FONKSĐYON ĐLĐŞKĐSĐ ÇALIŞMALARI 
 
Rashad Mammadov 
Malzeme Bilimi ve Nanoteknoloji 
Danışman: Doç. Dr. Đhsan Gürsel 
Ocak 2009, 107 sayfa 
 
Toll-benzeri reseptörler (TLR) doğal bağışıklık hücrelerinde ifade edilen 
patern tanıyıcı reseptörler ailesinin en çok çalışılan ve en kritik üyesidir. Bu 
reseptörler bakteri/virüs DNA’sı, gram negatif bakterilerdeki lipopolisakkaritler 
(LPS), gram pozitif bakterilerdeki peptidoglikan, maya mantarlarındaki zimosan, 
parazitlerdeki lipopeptidler veya profilin proteinleri, hatta virüslerdeki tek veya çift 
sarmallı RNA’lar gibi mikrobiyal işaretleri tanırlar. TLR ailesinin birçok üyesi 
arasından, mikrobiyal DNA üzerindeki metillenmemiş dinükleotid motifleri tanıyan 
TLR9 reseptörleri güçlü bir Th1 etkili enflamatuar yanıt başlatırlar. Metillenmemiş 
CpG motifleri taşıyan sentetik oligodeoksinükleotidler, bakteri DNA’sını taklit 
ettiklerinden bulaşıcı hastalıklardan kansere, alerji/astıma kadar birçok sağlık 
problemlerinin tedavisinde kullanılabilir olmalarının yanında bağışıklık koruyucu ajan 
ve patojenlere karşı korunmayı geliştirmek için aşı adjuvanı olarak da kullanılabilirler. 
Şimdiye kadar birçok CpG ODN sınıfı tanımlanmış, bunların fare ve insanlarda 
bağışıklık sistemini farklı şekillerde aktive ettiği gösterilmiştir. Yapı-fonksiyon ilişkisi 
analizleri göstermiştir ki tek zincirli lineer ODN’ler kompleks multimerik DNA 
kümeleri şeklinde formüle edildiklerinde farklı yönde bağışıklığa yol açmaktadırlar. 
Son zamanlarda Guanozilerce zengin CpG ODN’lerin kompleks kümeler oluşturup 
bağışıklık hücrelerini farklı şekilde yönlendirerek anti-viral bağışıklık oluşturduğu 
bildirilmiştir. Ancak bu çeşit ODN’ lerin klinikte kulanılması büyük ölçekli üretim 
esnasında üretimden üretime farklılıklar olması nedeniyle engellenmiştir. Bizim 
bilgimiz dahilinde, Guanozin zengini diziler haricinde kendi kendine nanoparçacık 
oluşturan DNA’lar bulunmamaktadır. Bu tez projesi dayanıklı, kendi kendine 
nanoparçacık oluşturan, G-yoksunu, CpG taşıyan ODN’ler ortaya çıkarmak için 
tasarlanmıştır.    
Bu tez çalışmasında yeni jenerasyon CpG ODN tasarlanmış olup yapısal ve 
bağışıklık sistemi üzerinde etkileri karakterize edilmiştir. Sonuçlarımız dendrimerik 
yapıların bilinen diğer ODN’lere kıyasla çok daha yüksek oranda bağışıklık uyarıcı 
potansiyelinin olduğunu önermektedir. Farelere in vivo ODN uygulamasından dört 
saat sonra, nanoparçacık oluşturan CpG ODN’lerin, kültür ortamındaki IFNγ ve IL-12 
üretiminden, dalak ve periton immün hücrelerini oldukça yüksek düzeyde aktive ettiği 
anlaşılmıştır. Hücreye alım ve bağlanma mekanizmalarını aydınlatmak için yapılan 
bloklama deneyleri en az bir çeşit skavenger (çöpçü) reseptörünün nanopartikül 
ODN’lerin hücreye alımında kritik rolü olduğunu ortaya çıkarmıştır. Sonuç olarak, bu 
verilerin ışığında nükleazlara karşı dirençli ve bağışıklık hücrelerine daha fazla 
bağlanmaları (ek bir ODN formülasyonu gerektirmeden) nanopartikül oluşturan CpG 
ODN kaynaklı bağışıklık aktivasyonuna katkıda bulunan faktörler olduğu 
söylenebilir. In vitro ve in vivo performansları bu yeni jenerasyon bağışıklık uyarıcı 
DNA’ların birçok klinik uygulama için güçlü adaylar olduğunu vurgulamıştır. 
 
Anahtar kelimeler: Doğal bağışıklık, TLR9, scavenger reseptörleri, nanoparçacıklı ve 
dendrimerik CpG ODN, immünterapi 
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1. INTRODUCTION 
Infectious diseases are one of the main causes of death worldwide. Although there is a 
significant decrease in mortality rate due to diseases caused by infectious agents, millions of 
people still die every year due to AIDS, respiratory infections, malaria, tuberculosis and 
diarrheal diseases (World Health Organization, 2008). More effective vaccines and biodrugs 
are needed to provide effective protection to these inflictions and decrease current mortality 
rate. In achieving this, a continued research effort is required in order to better understand 
how mammalian immune system recognize and discriminate non self “pathogens” and mount 
a response that leads to effective pathogen eradication before it causes any harm to the host. 
Developing novel strategies in order to accelerate this early immune response as well as to 
increase its magnitude and duration will help us to pave the way for better curative treatments 
during combat with these and newly arising deadly pathogenic diseases. 
Immune system while discriminating self from non-self, relies on a very simple rule. This 
dogma is known as the “Danger Signal” and is based on the recognition of specific signature 
molecules expressed on pathogens, and are missing on our cells. With this, innate arm of the 
immune system mount a robust orchestral activation in order to contain and furthermore 
eradicate the invading infectious organisms. This first line of defence not only contains the 
invading intruders but instructs the formation of a strong adaptive immune response first by 
migrating to the local lymph nodes and there attains the function of an antigen presenting cell 
that interacts with the T helper and B cells. This interaction controlled and initiated by the 
“Innate Immunity” leads to “Adaptive Immunity”. 
1.1. Innate Immune System  
Innate immune system has many arms which are so organized that they form several layers of 
barriers (that varies with their sophistication and complexity) in order to prevent the access of 
infecting organisms into the body (i.e. skin, mucous, cilia, tears, soluble proteins etc are some 
examples of this complex network). Infectious microrganisms, although rarely, find access to 
reach internal parts of our body, and due to rich nutrient sources, and availability of an 
optimum growth environment, they start multiplying inside our body at an unprecedent rate. 
At this stage, several ‘danger’ signals are wandering around and are recognized by one or 
many members of the innate immune system cells. Cells of the innate immune system 
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includes mucosal epithelia, dendritic cells (DC), macrophages (Mf), B-cells, natural killer 
(NK) cells, eosinophils, basophils and mast cells. Soluble components of the innate immune 
system includes, acute-phase proteins, complement system proteins, opsonins, polyreactive 
immunoglobulins (Ig) and mediators of immune response such as cytokines and chemokines. 
Mucosal epithelia, which is found in all metazoans, is the main barrier between host and 
microorganisms. Epithelial cells and keratinocytes secrete antimicrobial peptides to decrease 
colonization of microorganisms (Medzhitov R, 2007). Microorganisms that pass epithelial 
barrier meet with phagocytes (macrophages, dendritic cells and neutrophils) in local tissues. 
Resident macrophages recognize acute-phase and complement proteins, host plasma proteins 
that are already bound to bacterial surfaces (opsonization), and engulf microorganism with 
further initiation of bactericidal mechanisms - such as acidification, degrading enzymes, nitric 
oxide and antimicrobial peptide production which destroy microbes. Mf and DC induce a 
number of early acting cytokines and chemokines (please see Table 1.1. and Table 1.2.) which 
recruit neutrophils and monocytes to site of infection. Monocytes generally mature further 
into DC and Mf at infection site. NK cells are specialized cells to sense especially viral 
infections (already infecting a host cell) and induce death of these host cells (Janeway CA, 
2005). Eosinophils, basophils and mast cells are mainly involved in protection from 
multicellular parasites, while mast cells, also can sense microbial byproducts (Medzhitov R, 
2007).  Resident immature dendritic cells, which express numerous pathogen-recognition 
receptors (PRR) including Toll-Like Receptors (TLR) and Scavenger Receptors (SR) (these 
will be discussed in more detail in the subsequent sections), recognize certain microbial 
signatures and furthermore phagocytose them. Immature DC becomes mature and can no 
longer continue phagocytosis. They become Antigen Presenting Cells (APC) and migrate to 
draining lymph nodes. They are involved in further degradation and processing of microbial 
proteins for ‘antigen presentation’. This process is the sentinel stage that shapes adaptive 
immunity. The T and B cells are instructed and converted to antibody producing B-Cells, and 
effector T cells (Janeway CA, 2005).  
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Table 1.1. Cytokines affect behaviour of target cells (Adopted from Janeway CA, 2005).     
Mf: Macrophage, T: T-cells, DC: Dendritic cells, NK: Natural Killer cells 
 
Table 1.2. Chemokines induce chemotaxis of target cells to infection sites (Janeway CA, 
2005) 
Chemokines Produced by Attracted cells Major effect 
MIP-1α Monocyte, T, Mast cell , 
fibroblast 
Monocyte,NK, T, 
basophil, DC 
promotes Th1, antiviral defense and  
competes with HIV-1 
MIP-1β  Monocyte, Mf, Neutrophil, 
endothelial 
Monocyte, NK, T, 
DC 
competes with HIV-1 
MCP-1 Monocyte, Mf, fibroblast, 
keratinocyte 
Monocyte, NK, T, 
basophil, DC 
promotes Th2, activate Mf and histamine 
release from basophils 
IP10 T, fibroblast, endothelial, 
monocyte, keratinocyte 
Resting T, NK, 
monocyte 
promotes Th1, antiangiogenic, 
immunostimulant 
 
 
 
 
Cytokine Produced by Function 
IL-1β Mf, epithelial cells Fever, T cell and Mf activation 
TNFα Mf, NK and T cells Local inflammation and endothelial activation 
IL-6 B, T cells, Mf, endothelial T and B cell growth and differentiation, fever 
IL-12 Mf and DC Activate NK cells, induce CD4 T-cells to differentiate into Th1 
IL-15 Many non-T cells CD8 memory T cell survival, stimulates NK and T cell growth 
IL-18 Activated Mf Induce IFNγ secretion via NK and T cells, favors Th1 immunity 
IFNα DC Antiviral, increased MHCI expression 
IFNγ  T cells, NK cells Suppress Th2 immunity, Mf activation, increased expression of 
antigen processing components 
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1.1.1. Pathogen Recognition Receptors (PRRs) 
Microorganisms have shared structures, which are necessary for their survival like LPS 
(lipopolysaccharide), PGN (peptidoglycan) including single-stranded and double stranded 
genome of viruses or bacteria. Most of these molecules are recognized by host immune 
system and named as pathogen-associated molecular patterns (PAMPs). Certain properties of 
PAMPs fit very well with innate immune recognition of host (Medzhitov R, 2007): 
1) PAMPs are similar among different classes of microorganisms.  
2) PAMPs are molecules unique to microorganism world, thus immune system cells use to 
discriminate self and non-self.  
3) PAMPs have critical roles in microbial physiology, thus, these molecules can not be altered 
throughout the course of adaptive evolution. 
 
Specific innate immune receptors sensing these diverse structures is known as the pathogen-
recognition receptors (PRRs) (Medzhitov R, 1997).  Similar to PAMPS, PRRs also share 
common properties (Akira S, 2006): 
1) Each PRR recognizes a specific PAMP, activates signaling pathway and distinct immune 
response against pathogen 
2) PRRs are expressed constitutively by host immune system and detect the pathogens 
regardless of their life-cycle stage. 
3) PRRs are germline encoded, nonclonal, expressed on all cells of a given type, and 
independent of immunologic memory. 
4) They are highly conserved structures from plants and fruit flies to mammals  
 
PRRs can be classified as cytosolic PRRs which include nucleotide binding oligomerization 
domain (NOD)-like receptors (NLRs) and RIG-I-like helicases (RLHs) and membrane-bound 
PRRs which include Toll-like receptors (TLRs)  and Scavenger Receptors (SR) (Kumagai Y, 
2008, Mukhopadyay S, 2004). 
 
PRRs collectively are divided into two broad groups: i) non-signaling PRRs, such as 
Scavenger Receptors and ii) signaling PRRs, such as the famous family of Toll like receptors. 
This section will summarize the features of these major players of immunity.  
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1.1.1.1. Scavenger Receptors 
Scavenger receptors are large family of receptors expressed primarily by myeloid cells, but 
also expressed on selected endothelial cells (Mukhopadhyay S, 2004). They recognize various 
endogenous ligands such as phosphatidyl serine (apoptotic cells), low density lipoproteins 
(LDL) and its modified forms (acetylated LDL, oxidized LDL), modified proteins and also 
molecular patterns from foreign organisms. Scavenger receptors are divided into 8 major 
classes, mainly due to their molecular structure (Figure 1.1.). Among their diverse 
physiological roles, in accordance with the aim of this thesis, only the roles of scavenger 
receptors in recognition of microbial molecular signatures and their contribution to shape 
innate immunity will be covered . 
Class A : Scavenger Receptor class-A (SRA)- I/II, Macrophage Receptor with Collagenous 
structure (MARCO), Scavenger Receptor class A member 5 (SCARA5) and SR with C type 
Lectin-I /Collectin from Placenta receptor-I (SRCL-I/CL-PI) are members of this class which 
have roles in pathogen recognition. These receptors recognize different species of Gram-
positive and Gram-negative bacteria (Greaves DR, 2008) and modified LDL. Some of them 
also specialized in yeast (Saccharomyces cerevisiae) recognition such as SRCL-I 
(Mukhopadhyay S, 2004). SRCL-I was also shown to be involved in zymosan recognition and 
phagocytosis of fungi by human vascular endothelial cells (Jang S, 2008). Two well studied 
and known members i) SRA  and ii) MARCO will be covered briefly. 
 
SR-A I/II : SR-A, which is a trimeric type II transmembrane glycoprotein, has 3 isoforms - 
SR-AI, SR-AII and SR-AIII – that are alternative splice variants of same gene. SR-A was 
found to be expressed in myeloid cells (except monocytes), mast cells, specific 
subpopulations of bone marrow-derived and splenic dendritic cells (Plüddemann A, 2007). It 
binds to LPS (Hampton RY, 1991) and to LTA (Dunne DW, 1994) of Gram-negative and 
Gram-positive bacteria, respectively. Recently it is also reported that SR-A plays a role in 
recognition and internalization of dsRNA (Limmon GV, 2008).  However, SR-A was found to 
be not essential for uptake and immunostimulatory activity of K-type CpG ODN and E.coli 
DNA (Zhu FG, 2001, please note that “D-type” was not used in this study). SR-A-/- mice are 
more susceptible to Listeria monocytogenes (Suzuki H, 1997), Staphylococcus aureus 
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(Thomas CA, 2000) and Streptococcus pneumoniae (Arredouani MS, 2006) which shows 
critical role of SR-A in recognition of these pathogens. 
 
Figure 1.1. Classification of scavenger receptors. Each domain is indicated in the key above. 
(adopted from Plüddemann A, 2007) 
MARCO: MARCO is constitutively expressed by peritoneal and spleen marginal zone 
macrophages and also by medullary cord macrophages of lymph node (Kraal G, 2000). 
However, low level MARCO expression can be upregulated via TLR-mediated induction in 
macrophages derived from other sources (Doyle SE, 2004). CpG ODN (K-type) binding to 
peritoneal macrophages from MARCO-/- mice was unchanged, while CpG-induced IL-12 
production was severely impaired (Jozefowski S, 2006). MARCO recognizes LPS, LTA 
(Greaves DR, 2008), Gram-positive bacteria such as Streptococcus pneumoniae (Arredouani 
M, 2004) and Gram-negative bacteria such as Neiserria meningitides (Mukhopadhyay S, 
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2006). MARCO-/- mice infected with murine model of pneumococcal pneumonia, were 
unable to clear bacteria from lungs and showed decreased survival, while it induced increased 
cytokine release (Arredouani M, 2004). 
 
Class B : CD36 and Scavenger Receptors class B I (SR-BI) are the members of this family 
involved in innate immunity.  
 
CD36: CD36, type III transmembrane receptor, is expressed in microvascular (but not large 
vessel) endothelium, adipocytes, skeletal muscle, dendritic cells, epithelia of the retina, breast, 
and intestine, smooth muscle cells, and hematopoietic cells, including erythroid precursors, 
platelets, monocytes/macrophages, and megakaryocytes (Febbraio M, 2001). In addition to 
TLR2/6 heterodimer, studies showed that CD36 is indispensible for recognition of microbial 
diacylglycerides such as R-enantiomer of MALP-2 (a diacylated bacterial lipopeptide) as well 
as lipoteichoic acid (Hoebe K, 2005). CD36 was found to be critical for recognition and 
uptake of Staphylococcus aureus (Stuart LM, 2005). Finally, CD36 recognizes parasitic 
infection-induced membrane changes and mediates nonopsonic phagocytosis of P. 
falciparum–infected erythrocytes which is critical for malaria infected erythrocyte clearance 
(Febbraio M, 2001). CD36 has also been shown to have critical role in phagocytosis of 
apoptotic cells by macrophages (Fadok VA, 1998). 
 
SR-BI: SR-BI, which has 2 alternative splice variants - SRBI & SRBII, is expressed on 
monocytes, macrophages and dendritic cells (only in humans), and is also found on 
hepatocytes, adipocytes and adrenal glands (Plüddemann A, 2007). SR-BI and SR-BII 
mediate uptake of Mycobacterium fortuitum by non-phagocytic cells such as HEK-293 and 
might have a role in non-opsonized uptake of several bacterial species (Philips JA, 2005). 
Human SR-BI binds LPS (Vishnyakova TG, 2003) and E2 glycoprotein of Hepatitis C virus 
(HCV) (Scarselli E, 2002) and mediates their internalization (Barth H, 2008).  
 
Class C: Drosophila Scavenger Receptor-CI  (dSR-CI), type I transmembrane, plays a role in 
phagocytosis of gram-positive and gram-negative bacteria and the recognition of microbial β-
glucans in Drosophila (Mukhopadhyay S, 2004; Plüddemann A, 2007)  
 
  
8 
Class D: CD68 is not reported for pathogen recognition (Greaves DR, 2008). 
 
Class E: Lectin-like oxidised LDL receptor-1 (LOX-1), a type II membrane glycoprotein, is 
the only member of the class E (Plüddemann A, 2007). CHO-K1 cells expressing LOX-1 
stably have been shown to bind Gram positive and negative bacteria, which is Lox-1-
dependent (Shimaoka T, 2001). Moreover, it has a contribution to antigen cross-presentation 
by recognizing Hsp70 (Delneste Y, 2002). Recently, a link between TLR9 and LOX-1 has 
been reported. Activation of TLR9 via CpG motifs  increased LOX-1 expression (Lee JG, 
2008). CpG type used in this study wasn’t mentioned, while it was ROS-inducer from 
macrophages, so probably it was K-type CpG ODN. 
 
Class F: Scavenger Receptor (SR) expressed by Endothelial Cells-I (SREC-I) and SREC-II, 
type I transmembrane receptors, were not yet reported for any pathogen recognition 
(Plüddemann A, 2007; Greaves DR, 2008). 
 
Class G: Scavenger Receptor that binds Phosphatidylserine and Oxidized lipoprotein (SR-
PSOX), which is also known as CXC chemokine ligand 16 (CXCL16), is type I 
transmembrane molecule. SR-PSOX is expressed on macrophages and dendritic cells and in 
many organs (Plüddemann A, 2007). It can also perform function as chemokine ligand for an 
orphan G protein-coupled receptor Bonzo/CXCR6, when it is cleaved with ADAM10 –
metalloproteinase (Mukhopadhyay S, 2004; Abel S, 2004). SR-PSOX/CXCL16 can recognize 
and phagocytose Gram-positive and negative bacteria, and maintain adherence of cells to 
CXCR6 expressing T cells (Plüddemann A, 2007). Chemokine form might have critical role 
in inflammatory valvular heart disease by recruiting CD8+ T cells to inflammed tissues and 
enhance IFNγ production (Yamauchi R, 2004).  CXCL16 on plasmacytoid dendritic cells has 
been shown to recognize D-type CpG ODN and play critical role in its activity (Gursel M, 
2006) (see section 1.2.2. for more details). 
 
Class H: Fasciclin, EGF-like, laminin-type EGF-like and Link domain-containing scavenger 
receptor-1 and 2  (FEEL-1 and FEEL-2) are members of type I transmembrane proteins and 
are expressed on endothelial cells of the spleen, liver and lymph nodes. However, only FEEL-
1 is expressed on monocytes and macrophages (Plüddemann A, 2007). These receptors also 
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increase uptake of Gram positive and negative bacteria when expressed in non-phagocytic 
cells such CHO (Mukhopadhyay S, 2004). 
 
1.1.1.2. Toll Like Receptors (TLRs) 
Among PRRs, probably the most widely studied and famous member is the TLR family that 
includes 12 murine (TLR1-9, TLR11-13) and 10 human (TLR1-10) receptors identified so far 
(Takeda K, 2007). While some TLRs (TLR1, 2, 4, 5, 6 and 10) are located on the plasma 
membrane of the innate immune cells, others such as TLR 3, 7, 8 and 9 are located in the 
intracellular endosomal and/or ER compartments. TLR 10-13 are not well characterized. Only 
TLR11 among them is known to recognize protozoan profilin (toxoplasma gondii) and 
uropathogenic bacteria in mice. In humans they are non-functional due to stop codon inside 
the gene (Takeda K, 2007). Because of special focus of this thesis, TLR9 receptor for CpG 
motifs will be discussed in details as a seperate section (please see 1.1.1.3.). 
 
1.1.1.2.1. Extracellular TLRs 
TLR1, 2 and 6 : TLR2 differs from other TLRs. It can be activated by a heterotypic 
interactions either with TLR1 or TLR6. TLR2/TLR6 and TLR2/TLR1 were known to 
recognize diacylated and triacylated lipopeptides, respectively (components of bacterial PGN 
layer). CD14 and CD36 are necessary accessory molecules required for TLR2/TLR6 
activation (Miyake K, 2007). TLR2 is also triggered by zymosan from yeast and several 
glycolipids expressed by other specific bacteria (Takeda K, 2007). 
TLR4: It is the first identified TLR member (Poltorak A, 1998). TLR4, senses endotoxin 
(lipopolysaccharide LPS) found in outer membrane of Gram-negative bacteria. Lipid A 
portion of LPS is responsible for its toxicity. LPS binding protein (LBP) and CD14 are 
accessory molecules that have a role in recruiting LPS and transfer and load onto TLR4/MD-2 
complex (Miyake K, 2007). MD-2 is an accesory molecule, and its absence abolishes TLR4 
signaling. 
TLR5: Flagellin, a monomeric protein of bacterial flagella, is recognized by TLR5 receptor. 
Salmonella typhimurium does not induce inflammatory response in TLR5 knockout mice. 
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However, these mice were highly resistant to infections by this pathogen, where TLR5-
mediated inflammation seems to have role in microbial invasion of host (Takeda K, 2007).  
1.1.1.2.2. Endosomal/Intracellular TLRs (nucleic acid-sensing TLRs) 
TLR3:  Double-stranded RNA (dsRNA) appears during viral replication and induces type I 
IFN production. TLR3-/- mice have defective immune response against dsRNA (Alexopoulou 
L, 2001).  TLR3 knockout mice do not show high susceptibility to infection with most of 
viruses (Takeda K, 2007). 
TLR7/8: These two members are highly homologous and both of them recognize synthetic 
compounds, imidazoquinolines, which are clinically used for treatment of genital warts. That 
is associated with viral infection in humans and mice (mouse TLR8 is non-functional) 
(Takeda K, 2005; Takeda K, 2007). Moreover, TLR7 and human TLR8 recognize viral 
guanosine or uridine-rich single-stranded RNA (ssRNA) which is found in human 
immunodeficiency virus, vesicular stomatitis virus and influenza virus (Takeda K, 2005). 
 
1.1.1.3. Toll Like Receptor 9 (TLR9) 
1.1.1.3.1. Patterns Recognized by TLR9 as Stimulus 
TLR9 is the only known member of TLR family that can recognize specific DNA motifs. 
Hemmi et al., five years after the identification of CpG motifs, reported that TLR9 is 
responsible for recognizing the CpG DNA in mice. They showed that splenocytes, lymph 
node cells, dendritic cells, and macrophages from TLR9 null mice do not respond to CpG 
motif expressing ODNs (CpG ODN), as evidenced by the loss of pro-inflammatory cytokine 
production or cell surface maturation marker downregulation (please see table 1.2. for TLR9 
expression profile). Moreover, D-galactosamine (D-GalN) sensitized-mice are resistant to 
lethal effects of CpG ODN (Hemmi H, 2000). Then, it was shown that human TLR9 also is 
prerequsite for bacterial DNA/CpG DNA-dependent immunostimulation in both primary cells 
(B-cells and CD123+ DC) and TLR9 transfected cell lines (Bauer S, 2001; Takeshita F, 2001). 
Later findings challenged the idea that recognition of foreign DNA is restricted to CpG 
motifs. Non-CpG phosphodiester ODNs (PO-ODNs), which were delivered into endosomes 
after complex formation with DOTAP (Yasuda K, 2006), and self chromatin DNA/IgG 
autoantibody complexes (Boule MW, 2004) have been shown to be recognized via TLR9 and 
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stimulate innate immunity. Recently, TLR9 has been shown to recognize 2’-deoxyribose 
sugar backbone (base-free) of phophodiester DNA and activate cytokine secretion, but not 
phosphorothioate (PS) modified 2’-deoxyribose, PS or PO modified 2’-ribose backbones 
(Haas T, 2008a). Immunostimulatory activity and TLR9 affinity is increased further, when 
bases and CpG motifs were added to this backbone. PolyG addition (24 extra guanosines at 
3’end) or DOTAP complexations were used here to target sugar backbone or PD-ODN into 
endosomes. PS modified sugar backbones were highly affine to TLR9 and TLR7 
(significantly higher than PO-modified ligands) by PD-ODNs in vitro and in vivo (Haas T, 
2008a). 
 
Table 1.3. Variations in TLR9 expression among mice and human (adopted from Krieg AM, 
2006). 
  B-cells pDC mDC Monocyte/Mf 
Human yes yes no no 
Mouse yes yes yes yes 
pDC: plasmacytoid DC, mDC: myeloid DC. Mf: macrophage 
 
1.1.1.3.2. Mechanism of TLR9 Activation 
In non-stimulated cells TLR9 is localized to endoplasmic reticulum, which is transported to 
early endosomes and then lysosomes upon CpG stimulation to interact with CpG (Latz E, 
2004). Kim et. al, suggested that the transfer from ER to endosomes is mediated by 
UNC93B1 protein (Kim Y, 2008). Two independent studies, revealed that the ER to 
endosome docking was mediated by endosomal localization motifs present on TLR9 which 
are conflicting on region of these motifs at TLR9 protein (CA Leifer, 2006; GM Barton, 
2006). There is also other contradicting ideas on movement of TLR9 from ER to endosomes: 
Latz et al. reported that this is maintained by non-secretory pathway (Latz E, 2004), while 
Chockalingam et al. reported recently that secretory pathway is involved and TLR9 passes 
through Golgi on the way to endosomes (Chockalingam A, 2008). In endosomes, TLR9 exists 
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as homodimers, ligand unbound form is the inactive conformation of the receptor. When 
ligand (CpG DNA) binds, seperate TIR domains gets closer and recruit MyD88 for inititation 
of signaling cascade (Latz E, 2007). Fitting with this idea, it was shown that only aggregated, 
multimeric forms of ODNs are stimulatory. As concentration of multimeric forms increase in 
ODN solution, it becomes more immunostimulatory (Wu CC, 2004). Multimeric ligand seems 
to have more advantage to stimulate homodimer receptor, otherwise two monomeric receptor 
should be activated seperately with 2 different monomeric form of ODN at the same time in 
endosomes/lysosomes.  
Interaction of TLR9 with bacterial/viral DNA in endosomes of wild-type cells seems to 
prevent recognition of self-DNA, since artificially expressing TLR9 as chimeric protein 
(TLR9/TLR4) on the cell surface makes mammalian DNA stimulatory. Viral DNA becomes 
nonstimulatory in this case possibly due to existing protecting coat around the DNA (GM 
Barton, 2006). Mammalian DNA with phosphodiester backbone showed parallelism with PO-
ODNs, which become more stimulatory against surface expressed TLR9, in sensitivity to 
DNase. (GM Barton, 2006). This finding challenged previous notion accepting CpG motifs as 
a determinant of self/non-self discrimination. Lastly, TLR9 has been shown to get activated 
after proteolytic cleavage of carboxy terminal fragment at endosomes via cathepsin proteases 
(Ewald SE, 2008; Park B, 2008), which is concordant with previous data that TLR9 signaling 
is blocked by inhibition of endosomal acidification (Ahmad-Nejad P, 2002). This acidification 
is required for optimal activity of TLR9-cleaving proteases. These recent findings 
strengthened the hypothesis that TLR9 functionality at endosomes is mainly for self/non-self 
discrimination. Since to get activated, it should have to go to endosomes where self DNA 
does not have access.   
 
1.1.1.3.2.1. Accessory Molecules Involved in TLR9 Induction  
LL37: LL37 is an endogenous antimicrobial peptide which is expressed highly in psoriatic 
skin, which is an autoimmune disease of skin. During physical injury, disease condition 
worsens, self-DNA release and pDC activation occurs. LL37 form complexes with self-DNA 
to be delivered to early endosomes of pDC and stimulate IFNα production. Otherwise, self-
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DNA is inactive because it can’t colocalize with TLR9 in endosomes to stimulate it (Lande R, 
2007).   
HMBG1 and RAGE: HMBG1 (High-mobility group box 1) protein is a nuclear protein 
which binds DNA and is involved in bending of double-helix to increase affinity of DNA-
transcription factor interactions. In inflammatory cytokine stimulation, it is released from 
dendritic cells and regulates IFNα stimulation in an autocrine manner. Recent work shows 
that HMBG1 complexation with A/D-type ODN (but not B/K-type ODN) increases its B cell 
activating and IFNα-inducing potential from pDC. Moreover, this additional stimulation 
depends on interaction of RAGE (receptor for advanced glycation end-products), which is 
multi-ligand receptor of immunoglobulin superfamily, with HMBG1-TLR9 complex. They 
also showed that HMBG1 and RAGE have critical role in IFNα induction with DNA-
containing immune complexes in lupus patients (Tian J, 2007).  
Cathepsin-K: Cathepsin-K is an osteoclast-specific protease which is involved in degradation 
of bone matrices. It is seen as a therapeutic target to treat diseases, such as osteoporosis and 
autoimmune arthritis, in which osteoclast activity abnormally increases. Recently its role in 
CpG-induced TLR9 activation has been delineated (Asagiri M, 2008). Specific inhibition of 
Cathepsin-K by pharmacological inhibitor in dendritic cells, dose-dependently reduced TLR9-
mediated, but not TLR2 or TLR4-mediated, production of IL-12, IL-23 and upregulation of 
maturation markers such as CD40, CD80 and CD86 (Asagiri M, 2008). Moreover, cathepsin 
K-/- mice were refractive to stimulation with CpG ODNs but not with LPS, regarding IL-6 and 
IL-12 production from dendritic cells. 
 
UNC93B1: Missense mutation in Unc93b1 gene causes impaired signalling via TLR3 ,7, 9 
(called as ‘3d mutation’ due to defects in 3 different signal pathway) and exogenous 
presentation of MHCII. Mice with these mutations show increased susceptibility to murine 
cytomegalovirus (MCMV) infection (Tabeta K, 2006) . This impaired signaling is caused by 
defects in delivering these TLRs from endoplasmic reticulum to endosomes, which is 
mediated by UNC93B1 protein. TLR9 artificially expressed on plasma membrane is not 
affected from ‘3d’ mutation and responds to CpG motifs (Kim Y, 2008). 
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1.1.1.3.2.2. Signaling Through TLR9 
After 2h stimulation of TLR9-expressing cells with CpG ODN, number and size of CpG-
containing vesicles increases significantly, some of which co-stain with TLR9. Colocalization 
of TLR9 with CpG in same endosomes have been shown to depend on presence of 
intracellular ‘Toll/IL-1R homologous region’ (TIR) domain of TLR9. (Takeshita F, 2004) 
CpG-TLR9 interaction recruits MyD88, which is an adaptor protein involved in signalling 
through most of TLRs (for clear depiction please look Figure 1.2.). MyD88 deficiency 
completely impairs TLR9 signaling, which indicates that it does not use other adaptor 
molecules like several TLRs. MyD88 has two domains: TIR domain to interact with TIR of 
TLR9 and death domain (DD) to interact with interleukin-1 receptor-associated kinase-1 
(IRAK-1) and IRAK-4. IRAK-4 phosphorylates IRAK-1, which in turn upregulates its kinase 
activity, which leads to recruitment of tumor necrosis factor associated factor 6 (TRAF6)- E3 
ubiquitin ligase (Klinman DM, 2004b; Ishii KJ, 2006, Cao W, 2007; Kumagai Y, 2008b). 
TRAF6 stimulates the protein kinase TAK1, which in turn phosphorylates IκB to induce 
nuclear translocation of NF-κB and initiates signaling by the mitogen-activated protein kinase 
(MAPK) kinase family. Interferon production in pDC, is initiated at the early endosomes, 
IRF7 transclocates to nucleus, which is mediated by phosphorylation of IRAK1 and TRAF6, 
and starts type I interferon (IFN) expression (Cao W, 2007; Kumagai Y, 2008b). Recently it 
has been shown that when rapamycin sensitive PI(3)K-mTOR-p70S6K pathway is blocked 
through mTOR or downstream mediators, IRF7 activation and type I IFN production is also 
impaired due to inhibited interaction between TLR9 and MyD88 (Cao W, 2008). IRF5 is also 
an important transcription factor activated by TRAF6 and together with transcription factors 
NFκB and AP1 (activated by MAPK) it induces the expression of pro-inflammatory 
cytokines, chemokines and costimulatory molecules (Cao W, 2007).  
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Figure 1.2. Signaling pathway activated through TLR7 and TLR9 (Cao W, 2007) 
 
1.1.1.3.3. Cross-talk and Cooperation of TLR9 with other TLRs 
When a microbial infection takes place, cells of the immune system recognize the pathogen 
through interacting with multiple TLR ligands present on the pathogen surface. While it 
achieves this recognition and mounts a respond necessary for pathogen clearence, the 
response it generates must not harm self tissues. To achieve this, co-operation and cross-talk 
is necessary between different TLRs and other members of immune system. Recent evidence 
strengthen this hypothesis that sometimes TLRs synergize and induce an immune response 
which is quantitatively more than additive of individual TLR response. In other cases, one 
TLR member antagonizes the other and brings down the response generated.  
Several in vitro and in vivo studies have been performed and demonstrated that this 
cooperation does exist. Synergistic cooperation of TLR9 and TLR3 led to a more pronounced 
activation of TLR genes in, and proinflammatory cytokine production from mouse 
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macrophages (Tincer G, 2007 and Trinchieri G, 2007). During the course of Trypanazoma 
cruzi infection, TLR9 and TLR2 cooperates to resist infection. TLR2, TLR3, and TLR9 
contributes to control murine cytomegalovirus (MCMV) infection (Trinchieri G, 2007). 
During the Mycobacterium tuberculosis infection TLR9 and TLR2 cooperates to yield much 
stronger IL-12 (Th1 cytokine) induction. The double-knockout mice for TLR2 and TLR9 
revealed that IL-12 production is completely impaired, and none of the animals could survive 
after bacterial aerosol challenge (Bafica A, 2005).  
TLR9 along with other TLRs were also studied to establish whether there is a cross-talk 
between them. It was shown that TLR9 along with either TLR5 or TLR7, showed antagonistic 
character to certain TLR9-mediated immune effects. Substimulatory concentrations of TLR7 
ligands such as R848, loxoribine or ssRNA significantly antagonized IFNα production by 
A/D-ODN and C-ODN from pDC, when both ligands (TLR9 and TLR7) given together 
(Berghöfer B, 2007).  Moreover, when TLR5 and TLR9 were used together for stimulation, 
CpG-induced IFNα production and subsequent NK cell-mediated lysis were suppressed 
(Merlo A, 2007).  
 
1.2. Therapeutic Potential of TLR Ligands with Emphasis on TLR9  
1.2.1. CpG ODNs  
Oligodeoxynucleotide (ODN) sequences designed for antisense therapy were first shown to 
have immunostimulatory effect in 1992 by Yamamato et al. They observed that some of 
antisense ODNs containing palindromic sequences induced strong type I and/or type II IFN 
production and led to profound interferon mediated NK cell killing activity. Later, it was 
understood that unmethylated CpG motifs, which are nearly 20 times more frequently 
expressed in microbial DNA than mammalian DNA, are responsible for this immune 
activation (Krieg AM, 1995). CpG motif expressing ODNs stimulated murine B-cell 
proliferation and IgM production significantly, whereas control ODNs in which cytosines are 
methylated or CpG is inverted to GpC didn’t have any stimulatory effect. Minimum ODN 
length for stimulatory effect was 8 bp. Location of CpG was also important that methylation 
of 5’ CpG completely abolished while methylation of CpG at 3’ end didn’t reduce 
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immunogenicity of ODN (Krieg AM,1995). CpG ODNs stimulate BALB/c mouse spleen 
cells to produce IL-6, IL-12 and IFNγ. If a sequence contains multiple CpG motifs over its 
single strand, it increases its stimulatory effect. Number of cytokine secreting cells peaked 
after 12h stimulation which then declined gradually (Klinman DM, 1996). CpG ODN 
stimulates human PBMC also to release TNFα, IL12, IL-6 and upregulate monocyte and B-
cell activation markers. (Bauer M, 1999). They induce polyclonal activation and 
differentiation into plasma cells of memory B cells without BCR (B-cell receptor) signaling or 
T cell help which makes them powerful adjuvant for induction of humoral immunity. 
However, additional BCR signaling is needed for activation of naive B cells (Bernasconi NL, 
2002). Overall response to CpG ODNs by innate immune system is Th1-polarized. The 
immunization of mice with CpG ODN plus an antigen, induces IFNγ, IL-12, antigen specific 
IgG2a (all are Th-1 associated), and suppress IL-5 (Th-2 associated) production in response to 
specific antigen (Chu RS, 1997).  So far, specificity of sequences flanking CpG motifs were 
studied by many scientists. Central hexameric sequence should be PuPuCpGPyPy for mouse 
and PuPyCpGPuPy for humans to get optimal immune activation that substituting a Purine 
(Pu) for a Pyramidine (Py), or vice versa, significantly reduces or eliminates ODN activity 
(Krieg A, 1995; Verthelyi D, 2001). However, further sequences can be modified so that 
resulting ODNs elicit distinct immune profile. CpG ODNs designed up to now can be grouped 
into i) A/D-type CpG, ii) B/K-type CpG, and iii) C-type CpG which are discussed below. 
Moreover, additional less well established sequences, which do not fit to any of these three 
groups will be also covered.  
1.2.1.1. A/D type CpG ODNs 
This group of CpG ODNs is named as A-ODN by some groups and D-ODN by others. It will 
be referred to as D-ODN hereafter. D-ODNs have a mixed backbone of phosphodiester and 
phosphorothiote linkages. Generally, a single CpG motif is present within the middle of a 
palindromic region with phosphodiester (PO) backbone. This palindrome is capped by G 
(guanosine)-runs at both ends where the linkages between the guanosine pairs at 3` and 5` 
ends are phosphorothioate (PS) which confers resistance to exonuclease digestion. Minimum 
length of an active D-ODN is 18 bp. Representative sequences are given below:  
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1. D19:    5`-GGtgcatcgatgcagGGGGG-3` 
2. D29:    5`-GGtgcacggtgcagGGGG-3`  
3. D35:    5`-GGtgcatcgatgcaggggGG-3`  
4. D no poly(G):   5`-GGtgcttcgatgcaaaaaAA-3`   
5. D3CG:    5`-GGtcgatcgatcgaggggGG-3` 
6. ODN 2216 :  5’-GGgggacgatcgtcggggGG-3’  
Please note that lowercase letters indicate phophodiester linkages between bases, whereas 
uppercase letters indicate phosphorothioate linkages between bases. Bold bases are CpG 
motifs, and underlined bases represent unmethylated CpG dinucleotides.  
 
Inversion, replacement, or methylation of the CpG abolishes the stimulatory activity 
completely. The polyG ends (minimum 4 G at 3’ end is required for optimal activity) and 
central palindromic region of the ODN also contribute to D-type activity significantly 
(Verthelyi D, 2001). D-ODN has a high tendency to spontaneously assemble into higher-order 
structures, heterogenous particles mainly composed of globular (~50nm size) and linear 
structures (~100nm size), under physiological concentration and this structure formation 
depends on the presence of poly(G) motifs and on the palindromic region (Costa LT, 2004).  
The model for this multimerization was suggested by Kerkmann et.al., and according to this, 
two monomeric D-ODN form a duplex via Watson-Crick base pairing at their palindromic 
regions. Moreover, four poly(G) ends of the two duplexes are linked together via a non 
Watson-Crick base pairing. This is an interaction established between Guanosines and is 
known as “Hoogsteen Base Pairing”. The interaction between the planar four Gs is called “G-
tetrads” and multiple forms of these G-tetrads are named as G-Quadruplexes (Figure 1.3.). 
Exposing to high temperatures generally breaks down G-tetrads to their monomeric molecules 
(Kerkmann M, 2005).  
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Figure 1.3. Model for higher-order structure formation. G-tetrad links 4 D-ODN strands. 
(Kerkmann M, 2005)  
 
D-ODN induces high amounts of IFN-α/β directly from plasmacytoid dendritic cells (pDCs) 
and IFN-γ from PBMC (peripheral blood mononuclear cells). Maximum activity is reached at 
3 µM. They also indirectly induce IFN-γ, IP-10 from PBMC and NK cell activation strongly. 
NK cell-mediated IFN-γ production by D-ODN is IFNa/b-dependent, and IL12-independent 
(Krug A, 2001; Verthelyi D, 2001). They induce moderate levels of costimulatory molecules 
such as CD80, CD86 and HLA DR on pDC and B cells which are lower than K/B type CpG 
ODNs (Krug A, 2001). D-ODN stimulates monocytes to mature into CD83+/CD86+ dendritic 
cells which is IFN-α-dependent (Gursel M, 2002b). NK cell-mediated cytolytic activity, 
which is a very critical part of innate immunity against intracellular pathogens, was also 
increased considerably when PBMC (not pure NK cells themselves) were incubated with this 
type of CpG ODN (Krug A, 2001). D-type ODN stimulates mouse splenocytes to produce 
moderate IL-6, IL-12 and high levels of IFN-γ. Interestingly, IFN-γ induction by D-type ODN 
reaches maximal activity at 1µg/ml and declined as dose increased further (Vollmer J, 2004). 
Totally, these ODNs drive CD4 T cells to Th-1 direction.  The clinical future of this class of 
ODN is hampered by the fact that G-rich containing sequences are problemmatic during 
syntesis. Poly dG-based oligonucleotides lack pharmaceutical attributes due to unpredictable 
secondary structure formation depending on the experimental conditions, nonsequence-
specific protein binding, including immune stimulation (Wang D, 2008). 
 
1.2.1.2. K/B-type CpG ODNs  
 
This CpG ODN class is also called differently by different groups, B or K-type ODN. It will 
be referred to as K-ODN hereafter. These are full phosphorothioate backbone ODNs with at 
least one CpG motif, which is highly active as it is placed closer to 5’ terminus of the ODN, 
and at least one more base upstream of the 5`-CpG motif is required. Thymidine in the 
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immediate 5’ position is most favorable for humans (ODN2006). For mouse active CpG 
ODNs, CpG motif doesn’t have to be at the very 5’ end (ODN1555, ODN1826). Minimum 
length of ODN should be 12 bases for sustained immune activation, where ODNs with base 
number less than this have reduced activity on immune cells (Verthelyi D, 2001). This type 
doesn’t contain any polyG sequences and form any particulate complex structure under 
physiological conditions, it is believed to remain single stranded linear sequences (Costa LT, 
2004). Optimal K-ODN sequences for human and mouse are given below:  
 
1. ODN1826:   5`-TCCATGACGTTCCTGACGTT-3` 
2. ODN1555:  5`-GCTAGACGTTAGCGT-3` 
3. ODN2006:  5`-TCGTCGTTTTGTCGTTTTGTCGTT-3` 
4. K23:  5`-TCGAGCGTTCTC-3` 
 
K-ODNs trigger IL-6 and IgM secretion from B-cells and their proliferation. They also 
activate CD19+ B cells by upregulating CD69 (early activation marker) and CD25 (late 
activation marker) (Gursel M, 2002a). These ODNs are superior for maturation of pDCs and 
induction of proinflammatory cytokines from pDCs (Krug A, 2001). These ODNs can 
synergize with GM-CSF and activate the maturation markers of dendritic cells; MHC II, 
CD40, and CD83 (Hartmann G, 1999). Poor IFNα induction from pDCs is also characteristic 
of this type of ODNs, whereas it is reported that even this trace amount of IFNα is enough to 
induce MHC-I cross presentation in dendritic cells (Gray RC, 2007). K-ODN induced IFNγ, 
IP10 secretion from PBMC is little also if compared to other ODN types. However, 
splenocytes are stimulated better, regarding IFNγ response if mouse-active sequence is used. 
Spleen cells also secrete very high amounts of IL-6 and IL-12 in response to K-type ODNs 
(Krug A, 2001; Verthelyi D, 2001; Vollmer J, 2004). Mouse-active K-type ODN induces very 
high levels of nitric oxide (NO) from mouse-macrophage cell line (RAW264.7), whereas D-
ODN induces significantly lower NO amount from these cells (Utaisincharoen P, 2002).  
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1.2.1.3. C-type CpG ODNs  
C-ODNs have fully phosphorothioate backbone with 5’ CpG sequences (‘TCGTCG motif’) 
and 12-16 bp palindromic sequence at 3’ end for most optimal activity (Vollmer J, 2004). 
TCG at 5’ end is necessary for ODN activity as shifting it to 3’ end reduces IFNα inducing 
capacity. Nevertheless, 2-O-methyl (RNA-like) modification within the 5’-CpG motif led to 
complete loss of IFNα secretion. Immunostimulatory activity of C-ODN depends on the ODN 
length, the base content and a 5’-TCG. Further nucleotides from the palindromic region  at 3’ 
end do not have significant additive effect on stimulatory capacity, unless length of sequence 
is shorter for optimal stimulatory activity. Minimum length for optimal activity is 22 bp, 
where adding polyT to 3’ end of shorter sequences significantly increases their activity (Jurk 
M, 2004). Palindromic sequence, which is believed to allow duplex formation in an 
endosomal environment (Fig 1.4.), is vital for immunostimulatory activity of C-ODN (Krieg 
AM, 2006). Since similar sequences without palindromic property have severely reduced 
immunostimulatory effect, especially in the context of IFNα induction.    
 
 
Figure 1.4. Duplex formation through palindromic sequences by 2 monomeric C-ODNs 
(ODN2395).  (Krieg A., 2006) 
 
These ODNs were reported to combine the immunostimulatory activity of D-type and K-type 
ODNs. They directly activate human B cells with similar strength as K-ODNs (IL-6 secretion, 
proliferation and upregulation of activation markers such CD86) and induce IFN α production 
from pDCs weaker than D-ODN but stronger than K-ODN. They induce also higher levels of 
IFNγ, IP-10 from PBMC and upregulate activation markers on NK cells better than K-ODN. 
B-cell activation with this type of ODN is pronounced in whole human PBMC stimulation 
which is not the case for K type CpG ODN. IFNα production from pDC seems to have an 
additive effect to B-cell activation in whole PBMC stimulation. Depleting pDC from PBMC 
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lowers B-cell activation by C-type while it does not effect output of K-type stimulation of B-
cells, significantly (Hartmann G, 2003).   
Same sequences active in humans induce strong IL-6 and moderate IL12 and IFNγ from 
BALB/c splenocytes. Moreoever, mice immunized with mixture of recombinant HbsAg 
(surface antigen of hepatitis-B virus) and C-ODN induced several times higher HbsAg 
specific IgG2a isotype response, which is a clear demonstration of developing a Th1-biased 
immune response (Vollmer J, 2004).  
To sum up, C-ODNs are somewhere between D-ODNs and K-ODNs both structurally and 
immunologically. They are not linear as K-ODN but have tendency to form duplexes in body 
fluid, inspite of not forming highly multimeric structures as D-ODN. Immune profile is also 
somewhat mixture of ‘D’ and ‘K’ that they induce lower levels of interferon than D-type,  
whereas induce B cells directly as K-ODNs.  
 
1.2.1.4. Other Types of CpG ODNs  
In order to better modulate immune system, several different CpG ODN were designed other 
than ‘K’, ‘D’ and ‘C’ types. One of them is Y-shaped ODN which is formed by 3 linear CpG 
ODNs which have complementary regions with each other (Figure 1.5 ). This ODN have fully 
phophodiester backbone and induces higher levels of IL-6 and TNFα from RAW264.7 cells, 
from mouse macrophage cell line, than single- and double-strands of same ODNs when used 
with same amounts. It is claimed in that report than this potency in cytokine release is related 
with efficient uptake into macrophages (M. Nishikawa, 2008).  
Another work reported that 3’ extension of phophodiester linear (CpG or non-CpG ) ODNs 
with 24 guanine nucleotides turns these sequences into an effective IFNα inducer. Further 
extension doesn’t improve activity, whereas shorter polyG addition reduces. CpG motif has 
an additive effect to this stimulation. They showed that polyG addition confers complexation 
and efficient uptake into immune cells, like same sequences were mixed with DOTAP 
(complexation agent) (Haas T, 2008b).      
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Figure 1.5. Y-shaped CpG ODN (Nishikawa M, 2008).  
 
1.2.2. Differential Immune Response Mediated by Particulate and Linear CpG ODN. 
Although both D-type and K-type ODNs contain CpG motifs and initiate their effect by 
triggering through TLR9 receptor, and even if they stimulate same cell types (B-cell and 
pDCs in human) they end up inducing quite distinct immune activation from each other. 
Understanding mechanism behind this dichotomy is very critical, since it will help to 
modulate immune response by administering K- or D- type according to the desired therapy. 
Firstly, D-ODNs have been reported to localize to different vesicles than K-ODNs which is 
claimed to be due to poly-G motifs of D-ODNs. Moreover, D-ODN was taken up four fold 
more efficiently than K-ODN by PBMC, where excess concentrations of each ODN did not 
inhibit binding or uptake of the other (Gursel M, 2002a). Collectively these data suggest that 
these ODNs use different mechanisms of uptake. Poly-G tail, which confers particulate nature 
to D-ODNs, is possibly responsible in efficient uptake of D-ODNs. Higher efficiency of 
uptake of particulate ODNs into immune cells such as mouse macrophages and DCs (De Jong 
S, 2007; Anderson RB, 2008) and human pDC (Kerkmann M, 2006) has been confirmed by 
other studies. Furthermore, ‘Interferon Regulatory Factor (IRF)-7’ was found to be critical for 
IFNα induction from pDC by D-ODN, as pDC from IRF7-/- mice is unresponsive to D-ODN, 
while cDC (conventional dendritic cells) release cytokines such IL-12 and IL-6 upon D-ODN 
stimulation. K-ODN-mediated stimulation of pDC or cDC from this IRF7-null mice is not 
affected (Honda K, 2005a). Two recent works helped to explain this unexpected feature of D 
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and K ODN differential activity. Firstly, Honda K. et. al. reported that induction of different 
cytokines from pDCs by two types of ODNs is caused by different localization patterns by K 
or D-type ODNs in pDCs. D-type CpG oligodeoxynucleotides are retained for longer periods 
in the early endosomal vesicles of plasmacytoid dendritic cells, whereas K-type ODNs 
accumulate in vesicles with lysosomal markers (Honda K, 2005b). According to this model, 
D-ODN interacts with MyD88–IRF-7 complex in early endosomes, which results with IRF7-
mediated IFNα production. While, K-ODN activates MyD88-IRAK4/1-TRAF6 complex 
which activate NF-κB and IRF-5-mediated pro-inflammatory cytokine production (Asselin-
Paturel C, 2005). Retention of D-ODNs in early endosomes is facilitated possibly due to their 
higher-order structure, since artificial targeting of K-ODNs to early endosomes is achieved 
through making their complexes with DOTAP (Honda K, 2005b). These particulate forms of 
K-ODN induce IFNα comparable with D-ODN from pDC (Kerkmann M, 2005). Recruitment 
of D-ODN to early endosomes and their IFNα-inducing capacity seems to result from its 
interaction with CXCL16, a scavenger receptor only expressed on pDCs but not on B-cells 
(Gursel M, 2006). Gursel M. et al. showed that CXCL16 is necessary for localization of D-
ODN to early endosomes and initiate IFNα induction. Moreover, ODNs without poly-G tail, 
but with same sequence as D-ODN are unable to interact with CXCL16, which shows that 
interaction between CXCL16 and D-ODN depends on poly-G sequences (Figure 1.6.). 
Identification of specific receptor for D-type ODN might explain also higher efficiency of 
artificially multimerized ODNs, regarding uptake and immune stimulation (Shirota H, 2001; 
Haas T, 2008). To date, there is no convinving evidence showing that particulate forms of K-
ODN depends on additional recognition by cell surface receptor for immune stimulation. 
However, high potential for immune stimulation of nanoparticle CpG at doses where free 
CpG ODN is not active strengthens this hypothesis (Gursel I, 2001; Diwan M, 2004; 
Anderson RB, 2008).  
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Figure 1.6. Dichotomy of different CpG ODN types delivered to early or late endosomes 
induce innate or adaptive immune responses, respectively, in pDCs (Williams R, 2006). 
 
1.2.3. CpG ODNs as Therapeutics 
Critical cellular target for CpG ODN therapy are pDCs. Mice strains that do not possess pDC, 
couldn’t be protected against pathogenic infections. Moreover, pDCs from CpG-treated 
donors were able to mount protection in naive recipients. Another TLR-9+ cell type is B-cell, 
where CpG induces polyclonal activation of immunoglobulins that help to eradicate pathogen. 
NK cells and macrophages are indirectly activated by cytokines released upon CpG treatment 
from pDCs (Klinmann DM, 2004b).  
 
In an attempt to define the best optimum sequence effectively work on numerous outbread 
human populations, several hundred sequences covering broad range of motif sequences were 
synthesized and tested on PBMC isolated from over 100 donors. It has been observed that no 
single ODN is optimal for all tested individuals. Two strategies were suggested to overcome 
this polymorphism. One is synthesizing single ODN with different CpG motifs or using 
mixtures of multiple ODNs each expressing different CpG motifs (Leifer CA, 2003). This 
should be taken into consideration in therapeutic approaches with CpG ODNs, which are 
shown to be effective against infectious diseases, cancer, allergy/asthma.  
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Infectious diseases : CpG ODNs increase resistance even, of immunosuppressed, newborn 
and pregnant animals, to pathogenic infection. For example, in SIV (retrovirus like HIV)-
infected macaques D-type CpG ODN reduces parasitic (leishmania) load 1000 fold 
(Klinmann DM, 2004b). However, CpG treatment increases SIV load in macaques, probably 
by activation of infected T cells. As HIV infection doesn’t intefere with innate immunity until 
late stages of disease, CpG ODN therapy may be used to protect patients from other infections 
(Klinmann DM, 2004b).  
 
Moreover, induction of TH1 immunity by CpG ODN suggests that they can be used as vaccine 
adjuvants. CpG ODN + antigen immunization of mice has been shown to induce cellular and 
humoral immunity against antigens more powerfully than antigen alone. Chemical linkage 
between antigen and  CpG ODN boosts antigen-specific response further (Klinmann DM, 
2004b). 
 
K-type ODN and vaccine mixture increases anti-HB (hepatitis-B) IgG levels 60 fold when 
priming and 15 fold after boosting, to that compared of vaccine alone in cynomolgus monkeys 
(Verthelyi D, 2003). In another study, CPG 7909 plus vaccine induced Hepatitis B surface 
antigen (HBsAg)-specific antibody responses (anti-HBs) which appeared earlier and had 
higher titres from 2 weeks after the initial priming to 48 weeks individuals who received 
vaccine alone (Krieg AM, 2006).  
 
K-type ODNs have been shown not only to increase magnitude, but also accelerate 
development of  antigen-specific immune response. They increased specific antibody 
response induced by AVA (the licensed vaccine against anthrax) alone 6-fold, when 
adminstered together with AVA (Klinmann DM, 2004). 
 
Cancer : CpG ODNs encapsulated in sterically stabilized cationic liposome and recombinant 
interleukin-13 Pseudomonas exotoxin (IL-13-PE) were significantly effective against human 
neck and head cancer as xenografts in mice. CpG activity was dependent on NK cell activity, 
IL-13-PE increased this activity (Ishii KJ, 2003). In another study it was shown that K-type 
CpG ODN effectively suppresses metastasis of cancer cells, especially if they are 
administered after surgical removal of the primary colon tumor cells (Kim HA, 2008). For 
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small tumors CpG ODN seems to be effective alone, while for larger tumors CpG therapy 
should be combined with other therapies like chemotherapy, radiotherapy and etc. (Krieg A, 
2006).  For now, four different CpG ODNs are in clinical trials for treatment of 11 different 
cancers such as breast cancer and melanoma (Krieg A, 2008). Possible scenario of CpG anti-
tumor activity is illustrated at Figure 1.7. CpG ODNs activate NK cells via IFNα induction. 
Then NK cells induce death of tumor cells which causes tumorigenic antigen release to 
immune milieu. After processing antigens and getting matured, DC initiates antigen specific 
T-cell response against the tumor. 
 
 
Figure 1.7. Hypothetical effect of CpG ODN on tumorigenic tissue (Krieg AM, 2008)        
 
Allergy/Asthma :  Exact mechanism for therapeutic effect of CpG ODN on asthma is not 
clear. TH1 cytokines is not necessary for this (Kline JN, 2008). It is also reported that CpG 
ODNs conjugated with ragweed allergen have been shown in human clinical trials that 
redirect significantly allergy-associated TH2 immunity to non-allergic TH1 (Krieg A, 2006). 
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2. AIM AND HYPOTHESIS 
CpG ODNs are immune stimulating DNA based novel group of immunotherapeutics. 
Accumulating evidence both from preclinical and clinical studies indicated that CpG ODNs 
are effective against treating infectious diseases, asthma/allergy and cancer as well as 
improving the vaccine potency when included as an immunoadjuvants. Three major classes of 
CpG ODNs have shown to be effective in humans, the well studied class is the linear single 
stranded multiple CpG motif expressing K-type. The D-type CpG ODNs are unique due to 
several reasons, it stimulates a very special DC subclass known as the interferon factory, 
pDC. This differential activation of D type but not K-type is mainly due to the formation of 
multimeric aggregates of D-type (Kerkmann M, 2005). So far, the mechanism for this 
dichotomy between D and K-ODNs were reported to be the differential recognition by 
plasmacytoid dendritic cells. They expresses a surface scavenger receptor and D but not K-
ODN interact with this receptor, D-ODN then moves to a different subcellular compartment  
and possibly due to its multimeric nature it is retained for longer periods in the early 
endosomes (Gursel M, 2006 ; Honda K, 2005b). The signaling cascade initiated via TLR9, 
where scavenger receptors possibly have a role involves a transcription factor IRF7, which 
directs IFNα production by pDC (Wu CC, 2004; Honda K, 2005a; Guiducci C, 2006; Gursel 
M, 2006; Haas T, 2008).   
Antisense ODN complexations with polymeric dendrimers have been studied in the past by 
several groups (Kang H, 2005 ; Juliano RL, 2006 and Akhtar S, 2007). The major goal was to 
deliver ODNs within complexed polymeric nanoparticles (Santhakumaran LM, 2004). So far, 
no one have attempted to synthesize CpG motifs expressing ODNs on a dendrimeric structure. 
We have reasoned that this will confer more effective internalization as well as resistance to 
nuclease digestion and due to its nanoparticle nature will be stable and active until reaches to 
the site of the target immune cells. In this context, the present MSc Thesis project is carried 
out to explore the followings;  
1) To synthesize a dendrimeric CpG ODN and characterize its structural/physical properties, 
and understand the nanoparticle forming nature.  
2) To evaluate these dendrimeric CpG ODNs as a distinct class of new generation 
immunostimulants.  
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3) Finally, to understand the possible mechanism of dendrimeric ODN internalization by 
immune cells and its in vivo performance. 
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3. MATERIALS and METHODS 
3.1. MATERIALS 
3.1.1. Reagents  
All oligodeoxynucleotides (ODNs) and PCR primers were synthesized at AlphaDNA 
(Canada). Lower cases represent phosphodiester linkages whereas upper cases are 
phosphorothioate linkages for the ODN sequences. 
ODN 2006 (24mer) : 5`-TCGTCGTTTTGTCGTTTTGTCGTT-3` 
ODN1466 (10mer) : 5`-TCGACGTTGG-3` 
ODN1471 (10 mer) : 5`-TCGAGCTTGG-3` 
ODN1555 (15mer) : 5`-GCTAGACGTTAGCGT-3` 
ODN1612 (15mer) : 5`-GCTAGATGTTAGCGT-3` 
K23  (12mer) : 5`-TCGAGCGTTCTC-3` 
D35  (20mer) : 5`-GgtgcatcgatgcaggggGG 
ODN420 (70mer) : 7x 1466, (linked via symmetric bifunctional linker ; Scheme 
 3.1 A) 
ODN421 (70mer) : 7x 1471, (linked via symmetric bifunctional linker;  Scheme 
 3.1 B) 
ODN422 (90mer) : 9x 1466, (linked via symmetric bifunctional linker  and then 
 via trifunctional symmetric linker (Scheme 3.2 A) 
ODN423 (90mer) : 9x 1471, linked via symmetric bifunctional linker and then via 
 trifunctional symmetric linker (Scheme 3.2 B)  
ELISA reagents; i) paired antibodies for cytokines, ii) recombinant cytokines, iii) 
streptavidine-alkaline phosphatase (SA-AKP), iv) p-nitrophenyl phosphate disodium salt 
(PNPP) - substrate for alkaline phospahatase, were purchased from Endogen/Perbio, Pierce 
Biosciences (USA).  
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DNAse/RNAse free water,  RPMI1640 culture media and Na-Pyruvate, HEPES, Glutamate 
Penicillin/Streptomycin were all from Hyclone (USA).   
TRI Reagent for RNA isolation was obtained from Molecular Research Center (USA). 
DyNAmoTM cDNA Synthesis kit, DyNAzyme™ II PCR Master Mix for PCR were obtained 
from Finnzymes (Finland).  
DNAse I and its buffer were purchased from Roche (Switzerland). 
Stains-All dye, scavenger receptor ligands - dextran sulfate and fucoidan, control 
polysaccharide-chondroitin sulfate  were all purchased from Sigma-Aldrich (USA).  
10-150 bp DNA ladder was from Fermentas, and 100-1000 bp DNA ladder was from Jena 
Bioscience. 
 
 
SCHEME 3.1 A. ODN420: Schematic representation of the ODN420 formation via the use 
of bifunctional linkers at the 3`-end of ODN 1466 sequences. Synthesis was terminated at 
G=3.  
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SCHEME 3.1 B. ODN421: Schematic representation of the ODN421 formation via the use 
of bifunctional linkers at the 3`-end of ODN 1471 sequences. Synthesis was terminated at 
G=3 (third generation).  
 
SCHEME 3.2 A. ODN422: Schematic representation of the ODN422 formation via the use 
of bifunctional linker for G=2 and trifunctional linkers for G=3 at 3` ends of ODN 1466 
sequences. Synthesis was terminated at G=3.  
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SCHEME 3.2 A. ODN423: Schematic representation of the ODN423 formation via the use 
of bifunctional linker for G=2 and trifunctional linkers for G=3 at 3` ends of ODN 1471 
sequences. Synthesis was terminated at G=3. 
 
3.1.2. Buffers, Solutions, Culture Media 
For details of various culture media, different buffers solutions, and other assay solutions used 
throughout the thesis is presented in the Appendix I.  
3.2. METHODS 
3.2.1. Atomic Force Microscopy (AFM) 
10 µl of ODNs with different concentrations were deposited on glass coverslips and dried at 
room temperature under asceptic conditions.  Images were taken at Non-Contact mode using 
of PSIA AFM (XE-100E model, Korea). Multi75Al model tips were from Budget Sensors. 
Tips’ resonance frequency and force constant were 75 kHz and 3 N/m, respectively. Areas 
were scanned with 1-1.2 Hz rates (3 and 5 µm2).  Images were analyzed by using XEI 1.6 
software. For detection of the nanoparticle size and the size distribution following AFM 
study, at least 3 images were taken into account for each sample. At least 150-200 individual 
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particles were analysed during the computation of the average size and size distribution for 
each studied sample.    
3.2.2. Polyacrylamide Gel Electrophoresis (PAGE) 
ODNs were run in 20% polyacrylamide gel at 75V for 15min followed by 50V for 45min. 10 
µl from 10-150 bp range DNA ladder was used in the study. To visualize DNA bands,  gel 
was incubated in 0.005 % (w/v) Stains-All dye as it is suggested by manufacturer. After 2-3 
hr incubations (when bands become visible), gel was rinsed in ddH2O and exposed to UV or 
direct sunlight for a few minutes until the background gel staining was disappeared. The gel 
photo is captured under white light using (Vilber Lourmat, France) . 
3.2.3. Animals  
Adult female Balb/c (8-12 weeks old) were used for most of the animal experiments. Age 
matched C57Black/6 mice were used for strain comparison experiments. The animals were 
maintained in the animal holding facility of the Department of Molecular Biology and 
Genetics at Bilkent University under controlled ambient conditions (22o C ±2) regulated with 
12 hour light and 12 hour dark cycles. They were provided with unlimited access of food and 
water. Our experimental procedures have been approved by the animal ethical committee of 
Bilkent University (Bil-AEC).  
3.2.4. Cell culture 
3.2.4.1. Preparation of single cell splenocyte suspension culture 
Mice were euthanized by cervical dislocation. Spleens were removed by using sterile 
instruments and put into 2% regular RPMI media before starting cell culture experiment. In 
asceptic cell culture conditions, spleens were made single cell suspensions by squeezing them 
in a 6 cm petriplates using a back side of a sterile syringe in media. Homogenous part of  
media were collected by using sterile plastic pasteur pipettes avoiding cell clamps that are 
composed of fibrous or connective tissue. Cells were precipitated at room temperature (r.t.) by 
centrifugation at 1500 rpm for 8 to 10 mins using a Beckman centrifuge. Pellet was 
resuspended and washed twice with fresh media and used for further studies.   
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3.2.4.2. Cell counting & distribution 
After spleen cells were washed with a fresh media as indicated above, pellet were 
resuspended with 5% Oligo Media. 10 µl from these cell suspensions were taken and diluted 
10 fold with PBS to reduce cell number in the final 100 µl solution, (otherwise it would be 
very crowded to count the cells). 10 µl from diluted solution were micropipetted into Neubaer 
cell counting chamber. Cells in 4 corners (composed of 16 small squares) with 1mm2 area 
were counted under light microscope (Figure 2.1.).                                                            
                                                                                                  1mm 
                                                                                                                           
                                                                                                                        1mm         
                                                                                             
                                                                                                                                                                                                                                                
                                               
 
 
Figure 2.1. Neubaer cell counting chamber 
Each 1 mm2 area has 0.1 mm3/0.1 µl (depth between coverslip and counting chamber is 0.1 
mm) liquid capacity. So, number of cells/ml was obtained from the equation given below:  
           Total cell number in 4 squares       x 10 x 104 =  number of cells per ml.  
                                  4                            dilution factor            
             number of cells per 0.1 mm3 
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After determination of total cell number of the original suspension, for most of the 
experiments (unless otherwise stated) cell concentration was adjusted to 2x106/ml by diluting 
with 5% Oligo media. 200 µl from this suspension was added to each well of 96-well plate 
(4x105 cells/well). Cells were used for further treatments. For mRNA analyses experiments, 
cell concentration was adjusted to 107/ml.  
3.2.4.3. Stimulation Assay Protocols 
Splenocytes in 96-well plates were stimulated with titrating doses of several CpGs, control or 
D or K ODNs as well as dendrimeric ODNs during dose dependent-response assay. In other 
experiments stimulating concentration of ODNs were mainly adjusted to 0.5 µM. For the 
most part of the study, ODNs were freshly diluted with the proper cell culture media and 
adjusted to be 50 µl/well. In cases where, equal amount of ODN stimulation was used, ODN 
mixture was adjusted to 8 µg/well for each ODN type regardless of their individual molecular 
weights. Stimulations were performed in triplicate wells for each indicated treatment. 
Supernatants were collected after 48h for further analysis. For gene expression studies, cells 
were stimulated in 15 ml falcons with 0.5 µM of ODNs (depending on the type of ODN) for 1 
to 8 hours. During bulk cell stimulations to assay for mRNA analyses by RT-PCR the caps of 
the falcon tubes were left loose to allow airflow to the cells. Falcons were left in tilted 
position while plates with the lids on were incubated in CO2 incubator for various time points 
depending on the type of the experiment. 
3.2.4.4. Blocking Assays in the Presence of Scavenger Receptor Ligands 
Splenocytes in 96-well plates were treated with different concentrations of freshly prepared 
chondroitin sulfate (control),  dextran sulfate and fucoidan (scavenger receptor blockers) for 
30 min. The cells were then stimulated with 8 µg/ml of each ODN for 48h. Supernatants were 
collected for cytokine analysis.  
3.2.4.5. Experiments with ODN Pre-incubation  
Murine splenocytes were cultured as 4x105 cells/well in 250µl final volume of culture media 
(in 5% oligo media) in 96-well plates. After cells were pre-incubated with various ODNs for 
different incubation periods (from 1 to 8 h), they were spun at 200 g for 3-5 min. Cells were 
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washed twice with 250 µl warm fresh regular media to remove excess free ODNs remained in 
the culture (that were not taken up or bound at the surface of the cells at the end of the pre-
incubation period). Fresh cell culture medium was added over cells. Plates were incubated at 
37°C, under 5% CO2 up to 48h without further ODN stimulation. Supernatants were collected 
at several time points (6 to 48 h) and stored at -20°C for further analysis. 
3.2.5. Enzyme-Linked Immunosorbent Assay (ELISA) 
96-well PolySorp plates (F96 Nunc-Immunoplate, NUNC, Germany) were coated with 
monoclonal antibodies against mouse cytokines  i) IFNγ,  ii) IL-6 and iii) IL-12. 50 µl from 
antibody solution (10 µg/ml for IFNγ and IL-6 or 5 µg/ml for IL-12) were added to each well. 
Plates were incubated at room temperature for 5 hours or at 4°C for overnight. Solution in 
wells were discarded. Then wells were blocked with 200 µl blocking buffer for 2 h at RT or at 
4°C for overnight. Plates were washed with ELISA wash buffer 5 times with 5 min incubation 
intervals after each wash. Plates were dried by tapping (same washing procedure was repeated 
in upcoming steps).  Supernatants of cultured cells and recombinant proteins were added (50 
µl/well from both). Starting concentration for IL6, IFNγ and IL-12 recombinant cytokines are 
4000ng/ml, 500ng/ml and 500ng/ml, respectively. Recombinant cytokines were diluted 
serially (two fold with 1X PBS). Plates were incubated 3-4 hours at RT or overnight at 4°C. 
Plates were washed as explained above. After washing and blotting, 50 µl from 0.5 µg/ml 
biotinylated-secondary antibody solution (already 1/1000 diluted in T-Cell Buffer, please see 
Appendix I for details) were added to each well. Biotinylated anti-cytokine incubation was 
kept for another 2 h at RT or overnight at 4°C. Plates were washed 5 times using identical 
procedure as explained earlier in this section and dried by blotting. 50 µl from 1:5000 diluted 
streptavidin-alkaline phospahatase solution (SA-AKP in T-cell buffer must be prepared ahead 
of time at least one hour before pipeting) was added to each well. SA-AKP was further 
incubated for an hour at RT or overnight in the fridge. The washing step was repeated and 50 
µl of PNPP substrate was added to each well. Yellow color formation was followed and 
detected by several optical density measurements with (Biotek, Model: Microquant, USA, @ 
405 nm) until recombinant cytokine standards reached a four parameter saturation (S-Curve is 
obtained). All ELISA assays were performed in triplicate repeats for each treatment groups. 
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3.2.6. Quantification of Gene Expression by PCR Analyses 
3.2.6.1. Total RNA Isolation 
After stimulating splenocytes with various ODNs for 1h and 6h, 3-4 ml cold 2% 
regular media was added to each falcon and centrifuged at 1500 rpm for 8 min at 4°C . The 
media were sucked and pellet was resuspended with 4 ml cold media. After next 
centrifugation with same conditions, supernatant was sucked again. Pellet was dissolved with 
1 ml TRI reagent, mono-phasic solution of phenol and guanidinium thiocyanate, and cells 
were lysed. Cell lysates were either stored at -80°C till RNA isolation or immediately 
transferred into 1,5 ml eppendorf tubes for further RNA purification steps. All centrifugation 
steps were done at 4°C. For 1ml of TRI reagent was used in first step, 200 µl of chloroform 
was added to each eppendorf and then tubes were shaked vigorously for 15 seconds and 
incubated at room temperature for 2-3 min. Then eppendorfs centrifuged for 17 min. at 13.200 
rpm. The clear upper aqueous phase without touching the interphase were transferred into a 
new clean eppendorf tube. 500 µl of isopropanol was added for every 1ml of TRI reagent and 
mixed by inverting gently up/down to allow homogen mixing without shearing RNA. Then 
tubes were incubated at room temperature for 10 min. and centrifuged for 12 min. at 13.200 
rpm. In the next step the supernatant was removed and the pellet was gently washed with 1 ml 
of 75% ethanol (inverting the tube up/down for 6-8 times)  in order to exchange isopropanol 
and other remaining aqueous reagents with ethanol. Supernatant was discarded and pellet was 
gently washed with 1ml >99.9% ethanol and centrifuged at 8000 rpm for 8 min. After 
centrifugation, ethanol was removed and pellet was let to dry at RT under lamin-air flow hood 
in a tilted position. Dry pellets were dissolved with 20-30 µl RNase/DNase free ddH2O. The 
OD measurements were taken at 260 and 280 nm wavelengths with the spectrophotometer 
NanoDrop® ND-1000 (NanoDrop Technologies, USA). Purified total RNA samples were 
expected to have A260/A280 value between 1.8 to 2.2 ratio, which indicates minimal 
contamination with DNA, protein, polysaccharides or phenol. The RNA samples were stored 
at -80°C for further use. 
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3.2.6.2. Semi-Quantitative RT-PCR 
To detect relative mRNA expression level of TLR family genes, as well as pro-inflammatory 
and inflammatory cytokine and chemokine genes, semi-quantitative RT-PCR protocol was 
performed for the isolated total RNA samples from treated splenocytes as described in 
previous section. Briefly, a semi-quantitative RT-PCR assay includes cDNA synthesis from 
RNA, PCR by using specific primers for desired gene, gel electrophoresis of PCR products, 
meaurement and normalization of gel band intensities against a house keeping gene. 
3.2.6.2.1. cDNA Synthesis 
cDNA was synthesized from total RNA isolated from splenocytes (see Section 3.2.6.1. for 
details) according to manufacturer’s protocol. 1 µg from total RNA samples were mixed with 
1 µl Oligo(dT)15 primer (100 ng)  and completed to 8 µl with DNAse/RNAse-free water. 
Samples were incubated at 65°C for 5 min in MJ Mini thermocycler (BIO-RAD, USA). After 
being chilled on ice for 2-3 min, samples were mixed with 2 µl reverse transciptase (includes 
RNAse H+ inhibitor) and 10 µl reverse transcriptase buffer (includes dNTP mix and 10mM 
MgCI2). cDNA reaction was run in same thermocycler at these conditions:  10 min. @ 25°C, 
45 min. @ 40°C, 5 min. @ 85°C and then cooled down to 4°C. cDNA products were stored  
at -20°C unless they were used shortly after synthesis. Otherwise, they were kept at 4°C to 
prevent repeated freezing and thawing.  
3.2.6.2.2. Polymerase Chain Reaction (PCR) 
3.2.6.2.2.1. Primers for PCR  
Primers for il-6, il-18, cxcl16, ifnγ genes were designed using Primer3 Input 0.4.0 program 
(http://frodo.wi.mit.edu/primer3/input.htm) and Primer Designer 3.0 program with the cDNA 
sequences of the mouse homologues of these genes which are available at the Ensembl 
database. Each primer pair was blasted (http://www.ncbi.nlm.nih.gov/BLAST/) against mouse 
genome. Other primer sequences were obtained from literature (Table 3.1.) 
 
 
  
40
Table 3.1. The primer names, sequences, and expected product sizes of the primer pairs used 
throughout PCR assays. 
 
Primer  Sequence Product 
Size  
(base pair) 
β-actin 
 
Forward 
Reverse 
:5’-GTATGCCTCGGTCGTACCA -3’ 
:5’-CTTCTGCATCCTGTCAGCAA -3’ 
450 bp 
tlr-1 Forward 
Reverse 
:5’-TTTGGGGGAAGCTGAAGACATC -3’ 
:5’-CTTCGGCACGTTAGCACTGAGAC-3’ 
410 bp 
tlr-2 Forward 
Reverse 
:5’-TCTCTGGGCAGTCTTGAACATTTG -3’ 
:5’-CGCGCATCGACTTTAGACTTTG- 3’ 
320 bp 
tlr-3 Forward 
Reverse 
:5’-GGGGCTGTCTCACCTCCAC-3’ 
:5’-GCGGGCCCGAAAACATCCTT- 3’ 
250 bp 
tlr-4 Forward 
Reverse 
:5’-TGCCGTTTCTTGTTCTTCCTCT-3’ 
:5’-CTGGCATCATCTTCATTGTCCTT-3’ 
240 bp 
tlr-5 Forward 
Reverse 
:5’-TGGGGCAGCAGGAAGACG-3’ 
:5’-AGCGGCTGTGCGGATAAA-3’ 
380 bp 
tlr-6 Forward 
Reverse 
:5’- GCCCGCAGCTTGTGGTATC-3’ 
:5’-GGGCTGGCCTGACTCTTA-3’ 
650 bp 
tlr-7 Forward 
Reverse 
:5’-TTAACCCACCAGACAAACCACAC-3’ 
:5’-TAACAGCCACTATTTTCAAGCAGA-3’ 
700 bp 
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tlr-9 Forward 
Reverse 
:5’- GATGCCCACCGCTCCCGCTATGT - 3’ 
:5’-TGGGGTGGAGGGGCAGAGAATGAA- 3’ 
430 bp 
ip-10* Forward 
Reverse 
:5’-GCCGTCATTTTCTGCCTCAT- 3’ 
:5’- GCTTCCCTATGGCCCTCATT- 3’ 
127 bp 
tnf-α* Forward 
Reverse 
:5’-CATCTTCTCAAAATTCGAGTGACAA-3’ 
5’-TGGGAGTAGACAAGGTACAACCC-3’ 
175 bp 
il-1β Forward 
Reverse 
:5’-GCTGCTTCCAAACCTTTGAC- 3’ 
:5’-GGCCACAGGTATTTTGTCGT- 3’ 
431 bp 
il-6 Forward 
Reverse 
:5’-TGTGCAATGGCAATTCTGAT - 3’ 
:5’-CTCTGAAGGACTCTGGCTTTG- 3’ 
226 bp 
il-15* Forward 
Reverse 
:5’- CATCCATCTCGTGCTACTTGTGTT - 3’ 
:5’- CATCTATCCAGTTGGCCTCTGT - 3’ 
126 bp 
il-18 Forward 
Reverse 
:5’-ACAACTTTGGCCGACTTCAC - 3’ 
:5’- ACAAACCCTCCCCACCTAAC - 3’ 
491 bp 
mcp-1 Forward 
Reverse 
:5’- AGGTCCCTGTCATGCTTCTG - 3’ 
:5’- TCTGGACCCATTCCTTCTTG - 3’ 
249 bp 
cxcl16 Forward 
Reverse 
:5’- CGCTGGAAGTTGTTCTTGTG - 3’ 
:5’- GGTTGGGTGTGCTCTTTGTT - 3’ 
384 bp 
mip-1α Forward 
Reverse 
:5’- ACCATGACACTCTGCAACCA- 3’ 
:5’- AGGCATTCAGTTCCAGGTCA- 3’ 
238 bp 
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mip-1β Forward 
Reverse 
:5’- CCAGCTCTGTGCAAACCTAA- 3’ 
:5’- CTGTCTGCCTCTTTTGGTCA- 3’ 
250 bp 
ifnα 6/8 Forward 
Reverse 
:5’-TCTGATGCAGCAGGTAGAGATAC- 3’ 
:5’- CAAATGGTGCAGATACAAAAGTGG- 3’ 
384 bp 
ifnγ Forward 
Reverse 
:5’- GCGTCATTGAATCACACCTG- 3’ 
:5’- ATCAGCAGCGACTCCTTTTC- 3’ 
195 bp 
 
3.2.6.2.2.2. PCR Protocol 
All reagents were mixed and subjected to optimal PCR conditions for specific primer set in 
MJ Mini thermocycler (Table 3.2). Running conditions for ifnα6/8 were given at Table 3.3.a., 
for tlr9, ifnγ , il-6, and il-15 at Table 3.3.b and for the rest of the genes at Table 3.3.c. PCR 
products were kept at 4°C until run on agarose gel, otherwise stored at -20°C until for further 
use. 
Table 3.2. PCR reactants 
Reaction Ingredients Volume 
2x DyNAzyme™ II PCR Master Mix
* 
12,5 µl 
DNAse/RNAse free  H2O  9 µl 
Forward primer  1 µl (10pmol) 
Reverse primer 1 µl (10pmol) 
Cdna 1,5 µl 
Total 25 µl 
 
*2x DyNAzyme™ II PCR Master Mix includes 0.04 U/µl DyNAzyme™ II DNA Polymerase, 
20 mM Tris-HCI (pH 8.8 at 25°C), 3  mM MgCl2, 100 mM KCl, stabilizers and 400 µM of 
each dNTP. 
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Table 3.3. PCR Running Conditions 
a) 
                                 94 oC, 30 sec 
           94 oC, 2 min.            64.3oC, 30 sec       40 cycles         72oC,  10 min.           4 oC  
                                 72 oC, 1 min. 
b) 
94 oC, 30 sec. 
60oC, 30 sec.       34 cycles           72oC,  5 min.          4 oC 
72 oC, 30 sec. 
       
c)          
            94 oC, 30 sec. 
            55 oC, 30 sec.      34 cycles            72oC,  5 min.          4 oC  
72 oC, 30 sec. 
 
3.2.6.2.3. Agarose Gel Electrophoresis and Band Intensity Measurements 
1.5% agarose gel was prepared with 1X TAE buffer. Final concentration of ethidium bromide 
was 0,5 µg/ml in gel. 2 µl of agarose gel loading dye and 10 µl of PCR products were mixed 
and applied to each lane. 5 µl from 105 ng/µl DNA ladder with 100-1000bp range was used as 
a marker and the gels were visualized under UV transilluminator (Vilber Lourmat, France). 
The gel exposure time was kept fixed at 0.6 sec for each run, unless otherwise stated.  
Band intensity analyses were performed with BIO-PROFILE Bio-1D V11.9 sofware. Band 
intensity for every gene was measured and background intensity was subtracted from this 
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value. Blanked values for each gene were divided by blanked β-actin values (house keeping 
gene) to normalize resulting quantitative data.  
 
3.2.7. DNAse Treatment of the ODNs  
Dendrimeric ODNs and their monomeric forms were treated with DNAse I (1,2U/µg DNA) 
according to manufacturer’s protocol. In each reaction tube, there were 3 µl DNAse I (12U), 
10 µl ODN (10µg), 20 µl enzyme buffer and 37 µl ddH2O. After incubation at 37°C for 
varying time intervals, 4,8 µl from 0,1 M EDTA was added to each tube in order to chelate 
existing cations and to stop DNAse I protein digestion in the solution. Then tubes were 
incubated at 95°C for 5 min to achieve DNAse I inactivation. 20 µl of this solution was stored 
for PAGE experiments and the rest (40 µl) was used in stimulation of murine splenocytes. As 
a control, group of cells were treated only with DNAse I (including its buffer) to eliminate the 
possibility of immunogenic contaminantion by DNAse I or its buffer. At the end of the 
stimulation, supernatants were used to compare DNAse treated vs non-treated groups in terms 
of their ability to induce cytokine production (by ELISA)  and molecular integrity (by PAGE).    
 
3.2.8. ODN treatment of Animals and Detection of ex-vivo Responses  
Animals were injected intraperitoneally (ip) with 50 µg (high dose: HD) or 10 µg (low dose: 
LD) of  several ODNs (1-3 animals/group). As given below: 
1) Naive 2) ODN1466/HD, 3) ODN 1466/LD,  4) ODN 2006/HD, 5) ODN 2006/LD, 6) 
ODN420/HD, 7) ODN420/LD, 8) ODN421/HD, 9) ODN421/LD,  10) ODN422/HD and 11) 
ODN422/LD.  
Four hours after ip injection, peritoneal exudate cells (PECs) were removed by flushing 10 ml 
cold (5% Oligo RPMI1640) media into peritoneal cavity of euthanized mice and immediately 
collecting back with 10 ml syringe (with 30 gauge needle). Cells were layered into 24-well 
plate as 1x106 cells/well. After 36 hours supernatants were collected to measure cytokine 
production level. Spleens were also removed and splenocytes were cultured as 10x106 per 
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well. (please see Section 3.2.4.1. for single cell suspension preparation protocol). After 12h, 
24h and 48h supernatants were collected to analyze ex-vivo cytokine production.  
3.2.9. Statistical Analysis 
By using SigmaStat 3.5 software, statistical analysis between groups were done by pairwise 
two-tailed students` t-test to compare the statistical significance between naive, control and 
the ODN treatment groups in pairs.  
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4. RESULTS 
Nucleic acid based immunotherapeutics utilizing a subgroup of TLR family receptors 
(collectively known as endosome-associated TLRs) has been the focus of considerable 
research interest in recent years. Among RNA and DNA based ligands, CpG dinucleotide 
containing oligodeoxynucleotides  (hereafter CpG ODN) that are recognized by TLR9 
expressing innate immune cells constitute the most promising, DNA therapeutic candidate 
agents that will enter into clinics in the near future. While the ability for TLR9 to be 
differentially regulated by nucleic acids of varying sequence classes (D/A type, K/B type, or 
C-type ODNs) and structures offer flexibility for a broad spectrum of immunotherapeutic 
design, it also necessitates a more comprehensive characterization of these agonists in terms 
of how these structural parameters correlate with the divergent activation of unique cellular 
responses. Despite the utilization of three distinct classes of CpG ODNs as a TLR9 agonists in 
human trials as anti-cancer, anti-allergen, anti-infective or immunoprotective agents these 
issues have not been adequately addressed.  
Recent findings suggest that there is a dichotomy in the response between different classes of 
CpG ODNs (i.e. D vs K ODN types) [Verthelyi D, 2001; Gursel M, 2002a; Gursel M, 2006; 
Klinmann DM, 2004a; Klinmann DM, 2004b]. The studies delineating structure-function 
relationships demonstrate that, in addition to the number of CpG motifs on an 
oligodeoxynucleotide, the complex formation ability of specific sequences also affects the 
immunomodulatory performances of these ODN classes. G-quadruplex formation ability due 
to a poly G-runs at 3`ends of individual sequences as well as mixed backbone linkage 
chemistry between bases (i.e.  phosphodiester plus phosphorothioate linkages expressed on a 
single strand), were reported to trigger TLR9-mediated signaling cascade leading to type I 
interferon production by dendritic cells (as in the case of D/A type ODNs). Whereas pure 
phosphorothiote backbone modified sequences that may even express multiple CpG motifs on 
a single strand, initiates cell maturation, and Th1 dominant cytokine/chemokine production by 
innate immune cells (i.e. K/B Type ODN) in human and mice (Krug A, 2001, Klinmann DM, 
2004b).  
In this study, we attempted to design a novel multimeric CpG motif expressing ODNs-namely 
“Dendrimeric CpG ODNs” that are capable of forming complex higher order structures. The 
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original postulation was that these novel ODN structures will have spontaneous nanoparticle 
forming potential. The nanoparticle structure will offer several advantages over previously 
designed sequences. These novel sequences will induce i) superior immunostimulatory 
potential over conventional D and K type ODN classes, mainly due to ii) increased nuclease 
stability, iii) higher uptake level, iv) and yield reduced premature digestion/elimination when 
given in vivo.  This thesis is designed to address these issues as well as molecular 
characterization of these complex structures by physical techniques such as atomic force 
microscopy.  
 
4.1.  Synthesis of Dendrimeric ODNs 
A 10-mer single CpG motif expressing ODN sequence (ODN 1466) was used as the starting 
monomeric sequence in order to generate dendrimeric ODN structures. The ODN420 had a 
bifunctional symmetric linker added at the 3’- end of the ODN 1466. On to this bifunctional 
linker, two more ODN 1466 (please see section 3.1.1. for the sequence details) was further 
synthesized (this step constituted the first generation synthesis). On to each of these two 
strands again bifunctional linkers were attached, and ODN synthesis was continued form 
these linker ends (i.e each had two more ODN 1466 strands). This completed the second 
generation synthesis. In short, overall seven ODN1466 sequences were linked together (by the 
help of three bifunctional symmetric linkers), therefore, ODN 420 is generated. It had a base 
length of 70 mer oligonucleotide (US provisional  patent pending, 2008).  
The dendrimeric ODN (ODN421, Scheme 3.1 B) was synthesized using identical strategy 
explained above for the ODN420 as a control sequence lacking active CpG motifs. In that, 
ODN 1471 sequence was used as the starting monomeric sequence. Please note that the only 
difference between ODN1466 and ODN 1471 is the CG dinucleotide. It is flipped to GC in 
1471 sequence (See section 3.1.1. for the sequences).  
To synthesize ODN422  while first generation was completed by the use of a symmetric bi-
functional linker, in the second generation synthesis a tri-functional symmetric linker was 
used to link 3 ODN1466 sequences to the G1 strands. ODN422 yielded a nine sequences 
linked to each other and had a length of 90-mer oligonucleotide having a nine CpG motifs 
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linked on a dendrimeric strand (Scheme 3.2 A). Control sequence to ODN422 was 
synthesized in a similar fashion but here ODN 1471 was the starting monomeric sequence, 
thus, lacked active CpG motifs. (Scheme 3.2 B).  
 
4.2. Atomic Force Microscopy (AFM) Imaging of Dendrimeric ODNs 
The first and foremost feature of these novel sequences was to be able to display higher-order 
complex structures leading to DNA nanoparticle formations. To observe whether this was 
achieved, dendrimeric oligos were investigated with Atomic Force Microscopy (AFM) 
(please see section 3.2.1. for details). Different areas were scanned by the cantilever probe at 
non-contact mode and images were recorded for each dendrimeric ODN. Detailed analyses of 
the AFM micrographs revealed that ODN420 demonstrated uniform-sized nanoparticulate 
conformations (Figures 4.1A to D). While cantilever oscillations gave significant phase 
changes, the topography showed substantial altitude differences ranging from 20 to 30 nm 
individual peaks, indicating depth shifts among individual oligo sequences. The phase 
contrast AFM recording gives an idea about the solid existance of DNA particles on the glass 
coverslip, whereas topography data provide evidence on the individual heights of these solid 
entities that are scattered homogenously over the glass coverslip. Investigation of the 
specimen area at 3x3 µm surface revealed that when ODN420 and ODN421 dried on a 
silicone base they formed nanoparticles having an average size distribution of 35 ± 10 nm. 
Whether these colloidal structures are aggregates of several individual sequences or they are 
organized in singlets are not fully understood under these conditions. However, ODN422 
particles, differently from ODN420, appeared with high aggregation tendency. It seemed that 
individual particles can stick together to form bigger aggregates although individual particles 
are visible they are more sticky coalesced than ODN420 (Figure 4.2). To address the issues 
regarding aggregation status of ODNs, additional experiments were designed. One plausible 
approach was to run these oligos on Polyacrylamide gels (PAGE).     
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(A) topography (B) phase contrast
 
(D) phase contrast(C) topography
 
Figure 4.1. Bifunctional dendrimeric ODNs spontaneously form uniform-sized nanoparticles. 
10 µl aliquots from 1 µM ODN420 solution was deposited onto glass coverslips. Non-contact 
mode AFM was set to investigate the topography (A and C) and phase contrast (B and D) 
images. Scanned surface areas were 3 µm2  (for A and B) and 5 µm2
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(A) topography (B) phase contrast
 
Figure 4.2. Trifunctional dendrimeric ODNs tend to form heteregenous aggregates. 10 µl 
aliquots from 1 µM ODN422 solution was deposited onto glass coverslips. Non-contact mode 
AFM was used to get topography (A) and phase contrast (B) images. Scanned surface area 
was 5 µm2. 
 
4.3. PAGE Analysis of Dendrimeric and Conventional ODNs 
After observing that dendrimeric ODNs can yield homogeneous nanoparticles, the effort was 
chanelled to understand whether these structures are the result of single dendrimeric unit or 
several dendrimers are aggregating to yield a nanoparticle structure. As seen in Figure 4.3 
along with dendrimeric ODNs, several D and K type conventional ODNs as well as the 
monomeric ODN1466 were run on a polyacrylamide gel. The lanes were loaded with 10 µg of 
each ODN. The staining showed that ODN420 and ODN421 is suspended in the solution as a 
single monomeric unit as they aligned at the corresponding weight marker (at 70mer 
location). When the electrophoresis data and AFM images are taken together it is fair to 
speculate that the nanoparticles observed under AFM (for ODN420) belongs to a single 
dendrimeric unit rather than oligo agreggates whereas ODN422 is more heterogen than 
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ODN420 and thus the size distribution of nanoparticular aggregates under AFM appeared 
more dispersed. Gel image shows random multimerization of D35, as it appeared as a smear 
band on the gel. Removing G-rich sequences from D35 (D35-noPolyG) abrogates 
multimerization, which is observed as a single band on the gel. ODN2006, clinical grade K-
type ODN, is observed as single pure band. 
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Figure 4.3. Polyacrylamide gel electrophoresis of different types of ODNs. Several  
dendrimeric and linear ODNs were run on 20% polyacrylamide gel. To visualize the 
individual ODN bands, PAGE gel was incubated overnight in Stains-ALL solution at room 
temperature under dark. The gel was rinsed several times with ddH2O and exposed to UV or 
direct sunlight for few minutes. After bands became visible and the background was clear 
from the stain, the gel picture was taken by a digital camera under white light. 1466: 10mer, 
2006: 24mer , D35: 20mer, D35-noPolyG: 20mer, 420/421: 70mer, 422/423: 90mer. (BP: 
Base pair) 
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4.4. In vitro Stimulation Assays Using Mouse Spleen Cells   
4.4.1. IL-6 Production Mediated by Different CpG ODNs: Dose-dependent Treatment at 
Equimolar Concentrations 
After the encouraging AFM and PAGE studies implicating that the newly synthesized 
dendrimeric sequences formed nanoparticles, a series of experiments were designed to 
investigate the immunostimulatory activity of these ODNs along with conventional CpG 
ODN classes. The expectation was that the CpG ODNs capable of forming complex structures 
should yield superior immunostimulatory performance over conventional linear single 
stranded CpG ODN classes. Single cell suspensions of female Balb/c mouse spleen cells were 
prepared in warm fresh culture media, and plated at 2x106/ml  (4x105/well) final 
concentrations in 96 well plates. The cells were stimulated in triplicates with different oligos, 
at indicated titrating doses as given in Figure 4.4. Following incubation for 48 h, the culture 
supernatants were collected and stored for IL-6 cytokine detection with ELISA (please see 
section 3.2.5. for details).    
As seen in Figure 4.4 at 3 µM CpG dose, ODN420 (70mer) and ODN422 (90mer) were the 
most potent IL-6 inducers (over two fold more cytokine is secreted by ODN 420 and 422). 
This TLR9-mediated immune activation is strictly CpG motif dependent, since control ODNs 
(ODNs 421 and 423, where CG is flipped by a GC dinucleotides in these sequences) did not 
trigger any cytokine production in culture.  The ELISA results for ODN420 and ODN422 
sequences indicated that not only these sequences are active but also effectively internalized 
and fused with the endosomes (where TLR9 resides) of the immune cells. This initiates 
TLR9-mediated signaling cascade that led to the production of IL-6. Spleen cells are 
composed of TLR9 responsive B-cells, monocyte/macrophages and dendritic cells. Please 
note that T-cells also present in splenocyte culture but they do not express TLR9, thus, they 
are not directly stimulated by CpG DNA but rather they are induced by the 
cytokines/chemokines secreted by other immune cells in the culture. T cells then co-
stimulated by these mediators and contribute to cytokine secretion profile at a later phase. At 
this stage it is not possible to comment on the contribution of the specific cell type mediating 
the IL-6 production.  
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The dose-titration experiment was specifically designed to understand the strength of the 
stimulus generated by dendrimeric oligos. The potency of high dose oligo under in vitro 
conditions even though it is informative, is not a prerequisite for in vivo success. One needs to 
demonstrate that very low doses of a CpG ODN in culture can lead to substantially high levels 
of immune activation. Figure 4.4 suggested that at 0.1 µM concentration, ODN420 is still 
very active and led to nearly 26 fold more IL-6 production (7,7 ng/ml and 198,5 ng/ml for 
ODN2006 and ODN420, respectively). Of note, the sequences used along with dendrimeric 
oligos, are the optimum mouse sequences (1466 and 1555) and one of the most active human 
specific ODN (2006) sequence (also active in mouse), but none of these sequences were 
effective cytokine inducers at 0.1 µM dose. This group of data revealed that ODN420 but not 
ODN422 is active both at high and very low ODN doses. This is a very promising 
information. When an oligonucleotide is administered in vivo, a considerable amount of DNA 
would be eliminated from the circulation due to adsorption onto serum proteins and DNase 
digestion. Hence,  activity retention even at very low doses in culture provide an additional 
advantage to target cells that internalized these ODNs. Furthermore, if a strand, as in the case 
of dendrimeric oligos, is composed of several active CpG motifs, then a small amount of 
ODN binding would be expected to lead to sufficient activation.  The in vitro data presented 
in this section strongly support this view. 
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Figure 4.4. IL-6 production by murine splenocytes in response to dose-dependent CpG ODN 
stimulation. Varying doses of CpG and control ODNs were incubated for 48 h with spleen 
cells. Culture supernatants were collected and assayed for IL-6 production by sandwich 
ELISA. p <0,04 for 3 µM; p < 0,004 for 1 µM; p < 0,001 for 0,3 µM; p < 0,003 for 0,1 µM 
(420 and 2006 treated samples were compared for each dose).     
 
4.4.2. IFNγ and IL-6 Production Mediated by Different CpG ODNs: Treatment with 
equal weights of ODNs 
Although dose-response studies established that dendrimeric ODN is superior over other 
ODN classes tested, one may argue that dendrimer possesses multiple active CpG motifs on a 
single strand (eg. while ODN420 had 7 active motifs, single stranded ODN1466 oligomer had 
only 1, and ODN2006 had 4 CpG motifs over their strands, please see section 3.1.1. for 
sequence details), thus, treating cells with equimolar concentrations, with equal number of 
ODN molecules, would favor this class over the rest of ODNs in terms of the stimulation 
potential. 
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In order to resolve this issue, murine splenocytes were stimulated with equal weights of each 
ODN, where dendrimeric ODNs didn’t have an advantage over conventional ODNs in terms 
of CpG motifs. Supernatants were collected at the end of 48h stimulation with the indicated 
ODNs (8 µg/ml final concentration) and IFNγ and IL-6 production were assayed by ELISA. 
As seen in Figure 4.5. A and B, dendrimeric ODNs consistently induced significantly higher 
amounts of cytokine from spleen cells. ODN 420 gave five fold more IFNγ and 2 fold more 
IL-6 induction than ODN2006. Surprisingly ODN422 was found to be a mediocre IL-6 
inducer but a very strong IFNγ inducer in these assays. These results along with previous 
findings (please see Fig. 4.4) implicate that dendrimeric, nanoparticle forming ODNs are 
significantly superior over conventional single stranded linear CpG ODNs, and this ability is 
not entirely dependent on the number of CpG motifs expressed on a single strand, but rather 
the efficient internalization ability of these molecules.  
It is very important to mention that there is no strain difference in terms of the initiated 
immune response. We have compared the cytokine production by Balb/C strain throughout 
this thesis, but to understand if there is any strain to strain difference, we have run a 
stimulation assay side by side with the age matched Balb/C and C57/Black6. The IL6 and 
IFNγ responses were quite similar in spite of the strain differences (data not shown).  
A) 
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B) 
 
Figure 4.5. Cytokine response of murine splenocytes stimulated with equal amount of 
CpG/Control ODNs. Murine splenocytes were stimulated with 8µg/ml of each ODN for 48h. 
IFNγ (A) and IL6 (B) concentration at culture supernatants were detected by ‘sandwich’ 
ELISA method. p < 0,007 (between 420 and 2006), p < 0,03 (between 420 and 422) for  IFNγ 
and p < 0,001 (between 420 and 2006) for IL-6.   
 
4.5. Spleen Cells and ODN Mixing to Study Efficiency of Binding 
In previous section, treating spleen cells with different ODN types in culture either with equal 
amounts or equimolar concentrations, established that nanoparticle forming CpG sequences 
were more potent cytokine inducers compared to conventional single stranded CpG DNA. 
Several possibilities may contribute to this phenomenon. One reason could be the differential 
internalization of these ODN species by the immune cells. One of the best ways to assess 
direct ODN immune cell interaction is to use chromophore-labeled ODNs. Following mixing 
ODN with cells, binding and internalization of different oligos reliably quantitated via flow 
cytometry. Unfortunately, throughout this study, due to time restrictions and problems in 
synthesis, we could not obtain these labeled ODN sequences on time, therefore, an alternative 
experiment was designed to tackle this question. As mentioned in section 3.2.4.5., cells were 
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pre-incubated with different oligos for a period of time and then they were extensively 
washed with fresh warm media and further incubated in culture (no additional ODN is present 
in this media) for additional periods. Culture supernatants were collected after 6, 12, 24, and 
48h of post-incubation and cytokine ELISA was studied. It is important to note that the major 
goal was to allow ODNs to interact with the cells for a limited time, and then wash away the 
unbound free ODN from the culture medium. Previously, it has been demonstrated that up to 
8 hours of pre-mixing of cells with ODN lead to comparable cytokine secretion, similar to the 
unwashed counterpart (Yamada H, 2002). In the present situation the postulation was that 
depending on the type of ODN, different internalization (binding plus uptake) efficiencies will 
lead to varying cytokine induction levels. The extent of stimulation would be monitored by 
collecting supernatants at different incubation times.      
Several ODNs including dendrimeric ones (either at equal amount or at equimolar 
concentrations) were mixed with murine splenocytes for varying durations (0, 1h, 2h, 4h, and 
8h). Following extensive wash, the cells were suspended in fresh media and further cultured 
for different incubation times (cells were left for further 6, 12, 24, and 48h in culture) to 
monitor the level, as well as the extent of cytokine production at specific intervals in response 
to the internalized ODN during mixing steps. Supernatants from each treatments were stored 
for cytokine detection by ELISA.    
Table 4.1 summarizes the time course cytokine secretion for each CpG and control ODNs 
following pre-mixing with spleen cells at indicated times. While there is no detectable IL-6 
from the culture fluid after 1h mixing, detectable levels of IL-6 was obtained from the culture 
supernatants after mixing for 2 h and onwards. ODN420 secreted the highest IL-6 level at all 
pre-incubation times (4-5 fold more compared to single stranded linear ODN1466 or 1555). 
While ODN1466 or 1555 cytokine level in culture following 12 hours post-culturing subsided 
and dropped to a minimum detectable levels, IL-6 induction progressively increased by the 
cells that was pre-mixed with ODN420. This finding suggested that, internalized ODN420 
amount is sufficient to keep extended and continuous triggering of the cells and induce 
substantially higher levels of IL-6 secretion. The level of internalized linear ODNs probably 
does not reach this critical concentration inside the immune cells thus IL-6 induction 
remained significantly low throughout post-incubation period.     
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Next, an experiment was designed to confirm that short mixing time (2h mixing) does not 
initiate a non-CpG effect, here control dendrimeric ODNs were also included in the assay. 
Different form the data in Table 4.1, here equal amount of ODNs were used during mixing. 
Please note that, the limited exposure time allowed to cells during ODN mixing is one indirect 
way of simulating binding and uptake ability of different ODNs. Following washing and post-
incubation in culture to detect cytokine secretion by these pre-treated cells is a relevant 
assessment to understand the degree of response raised against intracellular ODN stimulation.  
Here, the expectation was that, the more ODN internalized by a cell, the more pronounced 
cytokine secretion by that cell would be achieved. Figure 4.6A, summarizes this outcome. As 
seen in Figure 4.6A, time-course cytokine production of spleen cells over the course of 48h 
post incubation was monitored. Similar to the observations mentioned above (in Table 4.1) 
only ODN420 consistently induced significantly higher levels of IL-6, and this effect is 
entirely CpG motif dependent, (the low level inductive effects of control dendrimers, 
ODN421, and ODN423 were undetected by 24h of post- incubation following washing)    
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Table 4.1. Mixing experiment: Murine splenocytes were pre-incubated with indicated ODNs 
for 2, 4 and 8 hours (indicated as 2h, 4h and 8h in the table). After washing, cells were further 
incubated with fresh media (without ODN) for 6, 12, 24, 48 hours (6, 12, 24 and 48h in the 
table) and supernatants were collected to perform IL-6 ELISA. 
 
 
 
* p < 0,010 between 420 and 1555 treated groups. N.D.: Not detected 
ODN-Cell mixing time                                         2h     
Post-incubation time 6h 12h 24h* 48h* 
Naive N.D. N.D. N.D. N.D. 
ODN1466 7,6 + 5,4 69,1 + 14,9 N.D. 19,5 + 13,2 
ODN1555 17,4 + 5,2 6,9 + 13,3 13,2 + 9,7 20,4 + 14,8 
ODN420 30,6 + 7,0 38,3 + 16,2 74,8 + 6,7 101,8 + 6,1 
ODN422 14,1 + 4,1 6,5 + 9,2 7,3 + 9,7 14,4 + 5,3 
ODN-Cell mixing time                                         4h     
Post-incubation time 6h 12h 24h* 48h* 
Naive N.D. N.D. N.D. N.D. 
ODN1466 14,1+ 27,4   N.D. 25,3 + 11,1 25,8 + 18,7 
ODN1555 28,8 + 24,7  8,9 + 9,1 38,2 + 10,6 34,3 + 14,9 
ODN420 7,4+20,8 39,4 + 17,5 143,8 + 9,5 119 + 24,4 
ODN422 8,7 + 13,5 11,8 + 10,5 60,7 + 9,8 29,5 + 9,0 
ODN-Cell mixing time                                         8h     
Post-incubation time 6h 12h 24h* 48h* 
Naive N.D. N.D. N.D. N.D. 
ODN1466 22,7 + 19,9 44,1 + 13,8 51,4 + 3,4 10,4 + 19,2 
ODN1555 29,8 + 24,6 33,6 + 14,2 41,8 + 12,8 N.D. 
ODN420 47,2 + 18,5 49,1 + 21,5  141,8 + 3,5    169,9 + 19,3 
ODN422 28,1 + 21,8 84 + 12,8  69,6 + 3,4 50,2 + 31,8 
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A) 
 
B) 
 
Figure 4.6. Mixing experiment. ODNs and spleen cells were mixed for 2h and washed and 
further incubated in fresh warm media upto 48h in culture. (A) Time-dependent IL-6 secretion 
profiles of ODNs from culture supernatants by ELISA. (B) IL-6 fold induction profiles of 
indicated ODNs. p < 0,004 (48h 420- and 1555-treated samples were compared)   
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To evaluate the maximum inductive capacity, a set of experiment was designed to monitor IL-
6 production from cell supernatants. In this set-up there is no ODN mixing and washing steps, 
instead ODNs were left in culture as before (as in Section 4.4.2.) throughout the stimulation 
period. Consistent with previous findings, among the tested CpG ODNs, dendrimeric 
ODN420 gave the highest IL-6 production (Figure 4.7A). Not only it induced detectable IL-6 
level as early as 12h post-treatment, it continued to trigger progressive cell activation and 
cytokine production steadily increased in culture over 48h period (please compare 12h 
induction level to that of 48h inductions for all ODNs in Fig 4.7 A).  Figure 4.7 B presents 
fold induction profiles of different CpG ODNs based on control ODN IL-6 levels.  
 
A) 
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B) 
 
Figure 4.7. Maximal ODN activity assay (no mixing and washing is done) using 8µg/ml CpG 
ODNs and control ODNs. (A) Time-dependent IL-6 secretion from collected supernatants by 
ELISA. (B) Fold induction in IL-6 secretion after 48h taking control ODN induction as the 
base for comparison. p < 0,001 (only the samples at 48h, for a, and b is calculated for 420 and 
1555 treated samples) 
 
4.6. Stability Assays of the Dendrimeric ODNs: Effect of DNAse Pre-treatment on CpG 
Mediated Immune Activation 
Previous section established that enhanced activation of dendrimeric ODNs in culture could 
be due to efficient internalization compared to single stranded CpG ODN counterparts. The 
other plausible explanation for the enhanced activity of the nanoparticle forming dendrimeric 
ODNs independent of efficient internalization could be due to the improved stability (i.e.  
better DNase resistance). This option also deserves better understanding since the dendrimeric 
ODNs are in complex forms, it is possible that even if they are not internalized better, when 
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taken up by spleen cells, they are more resistant to DNA endo or exonucleases and this may 
lead to enhanced activity.       
To understand if stability is contributing to the observed activity, series of experiments were 
designed. Before puting the CpG ODNs into stimulation assays, each DNA sample was 
subjected to DNAse treatment for a specific period. ODNs were incubated  for 10 or 20 
minutes with sufficient amounts of DNAse I (i.e. desired unit of enzyme needed to degrade 
specific µg of ODNs in 10 mins). As explained in the Section 3.2.7, DNase treated ODNs 
were subjected to PAGE analysis to visualize the level of degradation. Although a slight 
reduction in the band intensities was observed for  nanoparticle forming dendrimeric ODN 
(ODN420), gel pictures revealed that monomeric ODN (1466) is nearly completely digested 
at the end of 20 mins of enzymatic attack (Fig. 4.8A). Moreover, when murine splenocytes 
were stimulated with DNAse I-treated or non-treated ODNs (as a control group), DNAse I-
treated monomeric CpG ODN had lost its immunostimulatory capacity nearly totally (even at 
the end of 10 min), whereas dendrimeric ODN420 retained as much as  43 %  of its original 
activity even after 20 mins of DNase treatment (Fig. 4.8 B and Table 4.2). Surprisingly, 
ODN422 was very susceptible to DNAse I treatment, as evidenced by loss of gel band and 
cytokine induction potential.(see appendix and data not shown). 
 
A) 
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B) 
 
Figure 4.8. Dendrimeric nanoparticle forming ODNs (420,421) were resistant to DNase I 
treatment. ODN420, 421 & 1466 were treated with DNAse I for 10min and 20min. Then 
ODN samples were analyzed by PAGE (4 µg of each ODN/lane) (A) and furthermore used to 
stimulate splenocytes (8 µg/ml) for 48h. Culture supernatants were collected and IL-6 levels 
were checked with ELISA (B). 10` and 20` indicates time of ‘DNase treatment’ for each 
ODN.  
 
Table 4.2. Retained immunostimulatory potential of ODNs, in terms of IL-6 induction, after 
various treatment times with DNaseI.  
  10 min
* 
20 min** 
ODN 1466 7,8 ± 0,4 % 2,6 ± 0,4 % 
ODN 420 56,8 ± 15,2 % 42,6 ± 13,7 % 
 
* p < 0,006  ** p < 0,04 
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4.7. Blocking of Scavenger Receptor Interferes with Dendrimeric CpG ODN Mediated 
Immune Activation 
The mechanism of DNA or ODN binding and uptake is not well understood. Several single 
and double stranded ODN binding proteins as well as receptors responsible from recognizing 
charged molecules may play a critical role in this complex event. However, our novel design, 
nanoparticle forming dendrimeric ODNs are not just oligonucleotides but also act as particles. 
The most well known class of extracellular surface receptors known to interact with 
amphiphilic particulate entities on the cell surface, is known as the “Scavenger Receptors”. 
This class is diverse, and most innate immune cells are known to express them on their 
surface. 
It has been reported that specific scavenger receptors are required for the binding/uptake and 
recruitment to TLR9 positive endosomes when complex forming D-ODN class is interacted 
on the cell surface (Gursel M, 2006). To understand that if similar phenomenon is also 
required for the internalization, and thus, activity of nanoparticle forming ODNs we have 
embarked on a series of experiments. Several ligands are known to block scavenger receptors 
irrespective of their receptor types. Here, we have used several candidates to check whether 
internalization of specific ODN type are influenced by these ligands. Before the stimulations, 
ligands such as fucoidan and dextran sulfate were used to block cell surface scavenger 
receptors as it is mentioned in section 3.2.4.4.  As expected in some cases fucoidan was 
reported to be stimulatory (Kim MH, 2008), so its bloking effect was not observed (data not 
shown). However, dextran sulfate and control polysaccharide – chondroitin sulfate, which is 
not a scavenger receptor ligand, did not show any immunogenic activity when given alone on 
to splenocytes. As it is shown in Figure 4.9, pre mixing cells with dextran sulfate significantly 
blocked immunostimulatory potential of both dendrimeric CpG ODNs (ODN420 and 
ODN422, 50% to 90% respectively). This inhibition is specific to avoiding ODN/Scavenger 
receptor interaction as there is no suppression of ODN420, or ODN422 stimulation following 
chondroitin sulphate (another polysaccharide that shows non-scavenger receptor specificity) 
pre-incubation. Even at low dextran sulphate concentration this blocking was effective. The 
other striking observation is that linear CpG ODN sequences, as expected were not affected 
from dextran sulfate pre-treatment. Unexpectedly, very high doses of the blocker slightly 
increased the immune response mediated by these ODNs (Figure 4.9A). As expected pre-
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treatment with control polysacharide neither as such itself, nor over oligo sequences had any 
(inhibitory or positive) impact on spleen cell cytokine production profile (Figure 4.9B). 
 
A) 
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B) 
 
Figure 4.9. Effects of scavenger receptor ligand on CpG mediated immune activation. Murine 
splenocytes were pre-treated (30 minutes, at 37°C) with different doses (10, 20, 40, 80 µg/ml) 
of dextran sulfate (DS) and with control polysaccharide chondroitin sulfate (CS) (80 µg/ml) 
prior to stimulation with CpG ODNs. Culture supernatants following 48 h of incubation were 
analyzed for IL-6 cytokine by ELISA. Dose dependent effect of DS on maximal activity of 
each CpG ODN type (A). The effect of 10 µg/ml DS and 80 µg/ml CS after 30 min pre-
treatment on CpG mediated IL-6 release is plotted in (B). p < 0,006 for 420 vs 420+DS 
treatments and p = NS for 1555 vs 1555+DS.   
 
4.8. Gene Expression Profile of Murine Splenocytes Stimulated with Dendrimeric CpG 
ODNs 
In order to have more global understanding of the breadth of dendrimeric CpG ODNs` 
activity on the immune system, we can not use sandwich ELISA approach. As there are not 
available reagents for every cytokine/chemokine one wishes to study, we have decided to 
investigate the mRNA level of several other relevant genes including Toll-like receptor family 
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genes, as well as different proinflammatory, TH1, or TH2, and regulatory cytokine genes in 
addition to several proinflammatory and inflammatory chemokine transcripts from total RNA 
of spleen cells by PCR analyses. To differentiate between early activating and late activating 
genes, mouse splenocytes were stimulated for 1 or 6 hours.  
4.8.1. Effects of Dendrimeric CpG ODNs on Different Toll Like Receptor Gene 
Expression Levels 
The spleen cells were incubated for 1 or 6 h with indicated ODN, and cells were harvested 
and cDNA was prepared from the total RNA. In the presence of each tlr gene primer, PCR 
was run to evaluate the differential expression of the specific genes following ODN treatment. 
As seen in Fig 4.11 gel picture, dendrimeric CpG ODN420 did not induce significant TLR 
gene expression by 6h.  But the monomeric CpG ODNs significantly upregulated expression 
of several TLR family genes after 6h. Similar to single stranded linear ODNs, surprisingly, 
ODN422 showed significant inductive effect compared to naive or its non-CpG ODN423 
counterpart by 6 hours (compare band intensities for tlr 3, 4 and 7 genes, Figure 4.11).   
The important observation worth mentioning in this section is the unexpected feature of 
bifunctional ODNs. The band intensities by 6 h (including house keeping gene, β-Actin) the 
were significantly reduced (Fig 4.11 compare Naive vs 420 and 421 intensities for β-actin 
gene). We have invested substantial amount of effort to understand this unexpected 
observation. It seems that due to strong binding of dendrimeric ODN with the cell surface, we 
are co-precipitating the oligo together with the total RNA during RNA purification by TRI 
method (see Section 3.2.6.1.), and this contaminating dendrimeric ODN fraction is masking 
the gene amplification during PCR protocol (see appendix IV for details). Digestion plus 
extensive cell washing of the cells substantially reduced contaminating dendrimeric DNA and 
thus improved the relevant band intensities.  
But, nevertheless both ODN420 and 421 irrespective of CpG motifs, significantly reduced the 
expression level of the TLR family genes at all incubation times tested (1 and 6 h). (see 
Appendix II Relative intensity plots for individual genes) 
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Figure 4.10. Agarose gel image of PCR products of TLRs. PCR performed with TLR family 
primers and products were run on 1.5 agarose gel. The image was visualized under 
transilluminator and captured after 0.6 second exposure with UV.  
 
4.8.2 Effects of Dendrimeric CpG ODNs on Cytokine & Chemokine mRNA Expression 
Profile 
In addition to different TLR family genes, a panel of cytokines and chemokines of 
proinflammatory, inflammatory in nature was assessed by PCR. As done in previous section 
different CpG DNA species were incubated with the spleen cells, and the PCR was studied 
from the cDNA generated from the isolated total RNA of the cells. The dendrimeric CpG 
ODNs interestingly, behaved differentilly to different cytokine and chemokine gene 
epxression when 6h stimulation was analyzed. The ODN420 gave the highest upregulation for 
IL-6 gene (compared to K23 and ODN422), while TNFa and IL1b levels goes to baseline 
ODN422, and to an extent K23 highly upregulated these genes by 6h (Figure 4.12.). This 
piece of evidence strongly implicate that, ODN420 and ODN422 act differentially on the 
immune cells.  
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Table 4.3. CpG ODN-mediated expression levels of TLR genes normalized with 
housekeeping gene (β-actin).  
Gene/β-actin 
       TLR1  TLR2  TLR3         TLR4 
Stimulation time 1h 6h 1h 6h 1h 6h 1h 6h 
Naive  0,075 0,082 0,008 0 0,032 0,006 0,027 0,015 
1466 0,021 0,163 0,001 0,013 0,005 0,05 0,01 0,101 
420 0,009 0,005 0 0 0,007 0,018 0,009 0 
422 0,091 0,103 0,004 0,003 0,014 0,098 0,016 0,049 
Gene/β-actin TLR5 TLR6  TLR7  TLR9 
Stimulation time 1h 6h 1h 6h 1h 6h 1h 6h 
Naive  0,012 0,002 0,091 0,083 0,032 0,027 0,005 0,002 
1466 0,006 0,012 0,059 0,119 0,019 0,076 0,004 0,009 
420 0,003 0,004 0,037 0,014 0,018 0,021 0,002 0,003 
422 0,006 0,005 0,092 0,093 0,039 0,069 0,007 0,005 
For every treatment, relative band intensities of each TLR gene were divided by the same of 
β-actin gene. Green boxes represent upregulation, while red boxes represent downregulation 
with respect to ‘Naive’ samples upon CpG ODN treatment. 
 
β-actin
CXCL16
IL18
MIP1α
MIP1β
IFNα
IP10
TNFa
MCP1
IL6
IFNγ
IL1b
IL15
 
Figure 4.11. Agarose gel image of PCR products for cytokines/chemokines. PCR performed 
with cytokine/chemokine primers and products were run on agarose gel (for details please see 
Figure 4.11 legends). 
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When these gene activations were closely assessed by increasing incubation time,  
bifunctional dendrimer (ODN420) seemed to be more potent inducer of many arms of innate 
immune system since, expression of IL-6, IL-15, IFNα, IFNγ, and IP-10 significantly 
upregulated after 6 hours of stimulation. Some genes such as MIPα, MIP1β, IL-1β, TNFα  
were ‘early activating genes’ – upregulated at 1 hours (1h), but downregulated at 6h (Table 
4.3.). ODN422 however, behaved slightly different as it triggered separate genes such as IL-
1β,  CXCL16, IL-6, IFNα, IFNγ, IP10 after 6h. As expected, although ODN1466 were active 
it was significantly weaker stimulant than dendrimeric counterparts, with one exception, as it 
induced MCP-1 significantly higher than dendrimeric ODNs at the end of 6h (see Appendix 
III Relative intensity plots for individual genes).  
Table 4.4. CpG ODN-mediated expression levels of cytokine/chemokine genes normalized 
with housekeeping gene (β-actin). 
Gene/β-actin IL-1β TNFα IL-6 IL-15 
Stimulation time 1h 6h 1h 6h 1h 6h 1h 6h 
Naive  0,367 0,469 0,096 0,081 0,005 0,016 0,000 0,003 
1466 0,275 0,569 0,078 0,113 0,007 0,098 0,000 0,000 
420 0,608 0,042 0,169 0,113 0,026 0,367 0,000 0,047 
422 0,679 0,946 0,266 0,210 0,018 0,075 0,001 0,000 
Gene/β-actin IL-18 IFNα IFNγ IP-10 
Stimulation time 1h 6h 1h 6h 1h 6h 1h 6h 
Naive  0,206 0,021 0,003 0,007 0,027 0,012 0,500 0,470 
1466 0,107 0,033 0,006 0,006 0,020 0,036 0,471 0,483 
420 0,151 0,046 0,006 0,099 0,023 0,179 0,599 1,482 
422 0,183 0,030 0,006 0,018 0,044 0,163 0,509 0,862 
Gene/β-actin MIP-1α MIP-1β MCP-1 CXCL16 
Stimulation time 1h 6h 1h 6h 1h 6h 1h 6h 
Naive  0,000 0,000 0,006 0,001 0,040 0,262 0,040 0,092 
1466 0,000 0,000 0,004 0,018 0,007 0,479 0,040 0,079 
420 0,026 0,000 0,054 0,001 0,071 0,167 0,048 0,003 
422 0,000 0,001 0,024 0,023 0,055 0,254 0,050 0,142 
Green boxes represent upregulation, while red boxes represent downregulation with 
respect to ‘Naive’ samples and in some cases ‘1h’  of same gene upon CpG ODN 
treatment. For every treatment, relative band intensities of each cytokine/chemokine gene 
were divided by the same of β-actin gene. 
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4.9. In vivo Stimulatory Potential of Dendrimeric Nanoparticle Forming ODNs 
So far the data indicated that dendrimeric novel ODN sequences perform much better than 
single stranded linear counterparts, furthermore the spectrum of activation is much broader 
than the conventional sequences. It is of great importance to demonstrate that this enhanced 
activity attained to dendrimeric nanoparticle-forming ODNs translate itself when they are 
injected into Balb/c mice.  
To test in vivo efficacy of dendrimeric CpG ODNs, they were injected intraperitoneally to 
mice along with other conventional ODNs. Four hours after in vivo IP injection, cells from 
different sites were recovered and incubated in culture plates for further 12 to 48 h depending 
on the assay. Cytokine secretion profiles were analyzed from supernatants recovered either 
from peritoneal exudate cells (PECs) or splenocytes at indicated incubation periods (please 
see Figures 4.13 and 4.14). Among CpG ODNs injected to animals, ODN420 was the most 
active IFNγ inducer.  Nearly 2,5 fold higher levels than its monomeric ODN1466 and 35% 
higher than ODN2006 cytokine secreted by PECs (Figure 4.13A).  Similarly, IL-12 induction 
in PECs were the highest for ODN420. A 6-fold more cytokine production was detected 
compared to ODN2006. Monomeric ODN1466 induced undetectable levels of IL-12 when 
given in vivo. (Figure 4.13B).   
A) 
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B) 
 
Figure 4.12. Ex-vivo cytokine secretion from murine PECs. Murine PECs were collected 
after 4h from high dose (H) – 50 µg and low dose (L) - 10 µg ODN injected mice. PECs were 
cultured ex-vivo and IFN-γ (A) and IL-12 (B) concentration were checked after 36h  
incubation at culture. p = 0,004 for IFNγ and p = 0,021 for IL-12 (between 420 H and 2006 H 
groups). 
 
Splenocytes from ODN420 injected animal yielded the highest cytokine production, 
supporting the observation from PEC cells. In terms of IFNγ secretion from spleen cells over 
time, ODN420 stimulated nearly 2 fold more than ODN1466. 35 % difference between 
ODN420 and ODN2006 is not statistically significant.  Quite shockingly, ODN422 was found 
to be less active when given in vivo.  While it induced 3 fold more IFNγ than ODN420 at in 
vitro conditions, ODN420 could not reproduced this activity on both PEC and spleen cells 
after in vivo injection (please compare Figures 4.14 and 4.5A).  
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Figure 4.13. Ex-vivo cytokine secretion from murine splenocytes. Murine splenocytes were 
removed after 4h from high dose (H) – 50 µg and low dose (L) - 10 µg ODN injected mice. 
Splenocytes were cultured ex-vivo and IFN-γ concentration were checked at 12h, 24h and 
48h. p < 0,03 (between 48h 420L and 1466L). 
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5. DISCUSSION 
The discovery of CpG motifs and its ability to stimulate mammalian immune system sparked 
the oligodeoxynucleotide based immunotherapy. Since the appearence of the seminal paper in 
Nature journal in mid ninety several CpG based pharmaceutical companies were founded and 
they initiated several clinical trials utilizing synthetic CpG motif expressing DNA sequences 
aiming to treat diseases ranging from cancer to infectious diseases. CpG ODNs have been 
shown to mimic bacterial DNA and trigger innate immune cells that polarize immune milieu 
towards TH1. Establishing a TH1 type of immunity activates cytotoxic T cells and NK cells 
which kill infected host cells. This type of immune response has been shown to be effective 
against viruses, intracellular bacteria such as M. Tuberculosis, allergic reactions and cancer. 
With the description of the intracellular receptor recognizing CpG motifs, five years after the 
identification of the motif (Hemmi, et.al, 2000), TLR9 based immunotherapy gained a 
momentum and at present there are over 40 different clinical trial ranging from phase I to III 
are ongoing worldwide. 
In addition to the presence of CpG motifs on a strand i) backbone chemistry, (i.e. PS vs PO) 
ii) flanking sequences (PuPuCGPyPy or PuPyCGPuPy) iii) presence of runs of Gs at the 
terminal ends or iv) structural properties, of ODN sequence (i.e. presence of complementary 
sequences, or number of CpG motifs), and finally v) physical structure of the ODN (linear 
strands vs multimeric, or aggregated strands) have critical role in shaping the resultant 
immune response. For example, self-nanoparticle forming D-type CpG ODNs induce immune 
system differentially than linear K-type ODNs (main difference is type I IFN induction by D-
ODNs) which is due to longer retention of formers in early endosomes of target cells. Same 
phenomenon was observed for linear ODNs complexed with nanoparticulate carriers such as 
DOTAP liposomes or polymyxin (Haas T, 2008).  Moreover, nanoparticulate ODNs are 
recognized by scavenger receptors such as CXCL16, this confers an advantage over linear 
ODNs in terms of effective internalization. Another problem for linear ODN sequences seen 
when given in vivo is that the conventional CpG ODNs upon injection binds to serum proteins 
and degraded by nucleases before they reach to the site of target cells, and even before 
interacting with TLR9 in endosomes majority of the administered ODN is eliminated from 
circulation. Another problem seen during in vivo applications is the effective amount reaching 
to immune cells. Due to premature serum protein binding and nuclease digestionvery little 
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amount is internalized by the immune cells leading to a limited stimulation level, that harness 
the immunoterapeutic potential. Previously, an alternative method was developed to improve 
the in vivo activity of these CpG ODNs. Loading them on to nanoparticulate phospholipid 
carriers. By this approach it was shown that liposomal ODNs stimulate immune response at 
much lower doses and are less susceptible to DNAse attack. This make them potential 
candidates for improved in vivo applications (Gursel I, 2001). D-type ODN falls into 
spontaneously nanoparticulate forming structures. However, large scale synthesis of D-ODNs 
is not so easy because it shows batch to batch variation due to polyG runs at the ends of the 
ODN (Wang D,’ 2008). So, designing self nanoparticle forming ODNs without polyG runs 
which shows similar or better immune profile than D-ODN or, designing a novel ODN 
structure mimicking all known CpG-ODN classes but yet suprassing their in vivo performance 
is an important task. 
In this study, we designed 2 different types of dendrimeric ODNs aiming to obtain self-
nanoparticle forming structures, which will have higher immunostimulatory potential than 
linear CpG ODN counterparts. Analysis of these ODNs with Atomic Force Microscopy, 
which allows to investigate size and shape of molecules at nanometer resolution revealed that 
homogeneous DNA nanoparticles can be formed with this technology. Topography studies 
consistently displayed that ODN420 (using a bifunctional linker) dendrimer forms very 
homogenous structures reaching to a monodispersed size distribution around 35-40 nm in 
diameter. The ODN422 that was generated by using a trifunctional symmetric linker showed 
structures with heterogeneous shapes and varying sizes (20 to 55 nm). Phase contrast images 
also supported our topographical observations (please see Fig 4.1 and 4.2 for more details). 
Changes in the phase of cantilever oscillation can be attributed to any material present on the 
surface and does not implicate that these belong to ODN structures. However, when phase 
and topography images are compared, the phase shifts and topographical changes perfectly 
overlaped, these findings indicate that the observed nanoparticle structures are not caused by 
any contaminant or the roughness of the glass surface but merely belongs to the dendrimeric 
self nanoparticle forming ODNs deposited on the surface. 
The AFM micrographs although they provided encouraging findings, could only implicate 
that a complexed, multimeric ODN structures are formed after using a bifunctional linker 
throughout ODN synthesis. Under the lights of these findings it was impossible to predict 
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whether these nanoparticles were folded by itself to form self complementary (one molecule) 
aggregates or multiple strands were intertwined over each other to form molecule aggregates 
with more than one ODNs . To differentiate between these possibilities we performed PAGE 
analysis, which helped us to seperate nucleic acids accurately according to their molecular 
weights and/or sizes. Confirming our AFM images, PAGE gel pictures showed that ODN420 
had a homogenous population of DNA structures that corresponded to 70 bp Mol.Wt. marker, 
exact expected weight for a single dendrimeric 420 molecule. Collectively, AFM data and 
PAGE gel pictures suggested that ODN420 undergoes nanoparticle formation by folding over 
itself, rather than undergoing multimeric aggregate formation with other ODN420 strands. 
Different what is observed for ODN420, the second dendrimeric structure, ODN422, not only 
displayed a heterogeneuos appearance under AFM analyses, it gave a smear gel band after 
PAGE experiment, indicating that ODN422 complexation is an unstable one. The strand can 
interchangeably fold and unfold during complexation and the expected 90mer bp weight was 
not observed as a single band, but a smear was obtained in the gel pictures (please check Fig. 
4.3.).  
Next step was to compare the in vitro immunostimulatory potential of these newly designed 
CpG ODNs side by side with conventional mouse and/or human active ODNs. A dose-
dependent stimulation assay of mouse splenocytes revealed that the dendrimeric ODNs gave 
the highest stimulation at the optimum dose for the conventional ODNs. Moreover, dose 
titration significantly reduced the potency of all of the conventional ODNs but, ODN420 was 
capable of stimulating the splenocytes even at doses where other ODNs had failed to induce 
any response. Since the Molecular Weights of dendrimeric ODNs were significantly higher 
than other conventional ones, conducting experiments using equimolar concentrations during 
dose-titration assays favors dendrimeric ODNs in order to establish the activity of different 
classes of ODNs, and overcome this favor, we have repeated the same experiment using equal 
amounts of ODNs in the stimulation assays. Here, the weight was kept same, and thus for 
ODN1466, (single CpG expressing linear ODN) was equal in terms of active CpG motifs 
compared to ODN420 but for CpG 2006, the number of CpG motifs nearly doubled the CpG 
motifs expressed by ODN420. Consitent what we have observed for previous assay, similar 
findings were obtained here. The newly designed dendrimeric ODNs gave the most potent 
activity on spleen cells (Please compare Figures 4.5.A and 4.5.B with Figure 4.4.).  Despite 
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this advantage for ODN2006, ODN420 induced over two fold and eightfold more IL-6 than 
ODN2006 (note that this is a gold-standard CpG DNA and is a GMP lot provided by Coley 
Pharmaceuticals, Boston USA) and ODN1466 (monomeric type), respectively. Not only the 
amount of cytokines produced were higher, but the time of secretion was also extended when 
spleen cells were stimulated by ODN420. These results indicates that nanoparticle structures 
confers advantage to induce stimulation even at lower doses, which would be very important 
at in vivo applications where ODNs normally eliminated from circulation via serum protein 
adsorption or digestion by nucleases. IFNγ results were really surprising, ODN422 were 3-
fold more active than ODN420 and 15-fold more active than ODN2006. ODN1466 didn’t 
induce detectable level of IFNγ. ODN422 may be using additional entry mechanism to 
activate IFNγ secretion, which could be IFNα or IL12-dependent (please note that major IFNγ 
secreting cells, T cells, NK cells do not express TLR9, thus, IFN action is indirect). 
Aggregates with certain sizes other than ODN420 may be taken up by cells secreting either 
IFNα (pDC) or IL12 (macrophages) more efficiently. Collectively, these results (IL-6 and 
IFNγ) indicate that although CpG motif is indispensable for immune stimulation, the physical 
nature of the motif is critically contributing the final outcome. When stimulating cells with 7 
sequences of ODN1466 expressed on the dendrimeric structure immune cells secrete robust 
IL-6 and IFNγ, while with same sequences present on seperate strands, induce 8-fold lower 
IL-6 and undetectable IFNγ. These support that dendrimeric structure (possibly due its 
nanoparticle nature) confers significant advantage for immune stimulation. 
The enhanced activity of the dendrimeric ODNs could be due to either improved 
internalization, or improved nuclease resistance. To differentiate between these possibilities a 
series of experiments were conducted.  
Mixing experiments were designed to assess efficiency of binding between spleen cells and 
ODNs. Results of these experiments (Table 4.1, Figures 4.6 and 4.7) indicate that even short 
mixing time as early as 2h is enough for ODN420 to initiate long lasting stimulation and thus 
cytokine production (continuously increasing over 48h), while other ODNs gave immune 
response at basal level, which is non-detectable after 24 h post-incubation. Increasing 
incubation time increases response against ODNs. Immune stimulation by these dendrimers 
were strictly CpG motifs dependent, since GpC inverted counterparts were inactive. Mixing 
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experiments established that nanoparticle ODN induced far better stimulation than linear 
ODN even after very short term mixing of cells with the ODNs. The debate regarding the 
internalization vs nuclease resistance is still remained unresolved.   
To test nuclease resistance of the novel dendrimeric ODNs, several ODNs were treated for 10 
minutes and 20 minutes with sufficient amount of DNAse I to degrade them in 10 minutes. 
Results showed that ODN420 is highly resistant to DNAse I. While ODN1466 and ODN422 
were very susceptible and digested near to completion (Figure 4.8, Table 4.2 and data not 
shown) ODN420 was not effected by nuclease treatment. We can deduce from these results 
that improved DNAse resistance might be one of the mechanisms for ODN420 activation.  
Mixing experiments implicated that additional receptors might play a critical role for binding 
and subsequent internalization of the nanoparticle forming ODN. To understand that this 
might be the case we blocked scavenger receptors (a plausible candidate for recognition of 
nanoparticulate materials) with dextran sulfate ligands. ODN422 did not seem to have 
advantage over ODN420 during mixing experiments, but unexpectedly, more than 90 % of its 
activity was lost, that also indicate a dependence on scavenger receptors for cell entry. 
However, about 50% of ODN420-mediated activity was blocked by scavenger receptor 
ligands. Although high molecular weight (m.w.) ligands block scavenger receptors more 
efficiently than low m.w. ligands (personal communication with Dr. Mayda Gürsel), it is 
encouraging to observe that even 10kDa dextran sulfate yielded over 50% ODN420 
inhibition. More experiments are needed to be performed with different m.w. ligands in order 
to better understand ODN entry. Moreover, by using dye-tagged oligos, we could compare 
binding-uptake potential of novel ODNs before and after scavenger receptor blocking (Gursel 
M, 2006). Regarding the internalization mechanisms of ODN420 and ODN422, similar to D-
type ODN, which owes its activity to CXCL16, our nanoparticle forming ODNs possibly 
share similar type(s) of scavenger receptors. Blocking with dextran sulfate didn’t seem to 
affect immune-activating potential of ODN1466 and ODN1555 which are K-type, linear 
sequences. In fact, in some cases they even synergised with dextran sulfate to induce more 
pronounced cytokine secretion. 
To understand the breadth of immune response as well as the impact of turning on or off other 
TLRs, we wanted to check expression level of TLR and several cytokine/chemokine genes at 
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mRNA level after stimulating splenocytes with ODNs. As expected, the nanoparticle forming 
ODN420 did not seem to regulate tlr genes, (if not suppressed), while its monomeric form 
strongly induced expression of nearly all TLR panel at the end of 6h. ODN422 was mediocre 
and induced some of the endosomal TLRs (i.e. TLR3 and 7) and TLR4.  These results suggest 
that there might be regulatory mechanism for tlr genes controlled by inflammatory status of 
cells.  
As an example to early immune related gene activation, ODN420 induced MIP1α, MIP1β as, 
IL1β, TNFα, IL-6 levels, while , IL-15, IFNα, IFNγ, IP10 were upregulated as a late response 
genes. It is important to note that, MIP1α, MIP1β (recruiting T and NK cells) , IL-15 
(activates NK cells), IFNα, (primary antiviral cytokines, activates NK cells) IFNγ, IP10 
(stimulates TH1 response) are cytokine/chemokines that are frequently upregulated during 
viral infection. This allow us to speculate that homogenous nanoparticle size of ODN420 may 
mimic DNA viruse entry and instruct immune response to get prepared for a viral infection. 
ODN422, however stimulated , IL1β, TNFα, MIP1β (early and late), IL-6,  IFNα (lower 
amount), IFNγ, IP10, CXCL16  (late). While ODN422 didn’t downregulate any of the 
cytokine/chemokine genes, ODN420 downregulated MIP1α, MIP1β, IL1β, TNFα and 
CXCL16 at the end of 6h. We think these data also support our hypothesis that cells 
downregulate early proinflammatory cytokine/chemokine genes to block harmful 
inflammation after immune response reaches a peak.  It is of importance to emphasize 
CXCL16 downregulation, which we speculate here that might be showing critical role of 
CXCL16 in ODN420-mediated immune activation. In the literature, there is no evidence for 
the CXCL16 mediated virus entry, but our hypothesis is that this receptor is act like a 
nanoparticle recognition receptor; upon ODN420 stimulation, cells may want to prevent more 
virus entry by downregulating CXCL16. This provocative idea, must be supported with 
further experiments.  
We have promising results with regard to i) dendrimeric ODN synthesis, ii) physical 
characterization to establish their spontaneous nanoparticle formation, iii) the enhanced in 
vitro binding, uptake, nuclease resistance, that collectively translated in to very potent 
stimulator designed so far, also iv) the activation of multiple cytokines and chemokines at the 
transcript level were identified. Lastly, within the scope of this thesis, the ability of the 
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nanoparticle forming dendrimeric ODN when administered in vivo was analyzed. We 
compared several conventional ODNs along with our dendrimeric ones, and checked cytokine 
secretion (IL-12 and IFNγ) from spleens and peritoneal exudate cells (PECs) removed from 
ODN injected mice. Confirming our in vitro observations, ODN420 were significantly more 
potent than any other tested ODNs at inducing ex-vivo cytokine secretion. In spite of higher 
IFNγ secretion potential of ODN422 at in vitro, perhaps due to its DNase susceptibility as it 
was not successfully conforming nanoparticles, behaved less potent than ODN420 on both 
splenocyte and PEC samples (similar to the observations in mixing experiments). 
To summarize, dendrimeric structure provides superior immunostimulatory properties over 
conventional ODNs, which might have direct relationship with spontaneous nanoparticle 
formation. Bifunctional dendrimers induced were potent activations both in vitro and in vivo, 
situations, while trifunctional ODNs seemed to be less effective (to translate their in vitro 
performance to in vivo settings). However, dendrimeric structure have synergistic effect with 
CpG motifs as CpG + dendrimer is more powerful than only CpG. ODN420 stimulates 
mainly anti-viral cytokines, suggesting that it might be used as antiviral agent in the future.  
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6. FUTURE PERSPECTIVES 
The present study is the first to document that a single stranded oligodeoxynucleotides when 
joined together via their 5` to 3` ends using a bifunctional symmetric linker is capable of 
undergoing complex conformation dependent change leading to self nanoparticle forming 
DNA structures. These novel CpG motif expressing sequences were further characterized via 
biochemical and biophysical methods that they are homogeneous nanoparticles. The 
immunological assays further established that dendrimeric ODNs are more resistant to 
nuclease attack, internalize more to immune cells than conventional linear-single stranded 
ODNs and yield more pronounced immune activation compared to conventional ODNs as 
evidenced by Th1 dominant cytokines and several chemokines. This thesis work also provide 
evidence that nanoparticle forming CpG ODNs are entering into the immune cells via 
interacting with a scavenger receptor and moreover is active in vivo, inducing significantly 
more immune activation to that of conventional ODNs. 
 
Our understanding of dendrimeric CpG ODN mediated immune activation must be further 
studied in details. First of all, it is instrumental to assess whether this approach could be 
applied to several other sequence motifs, and consistently improves the activation potential 
compared to single stranded conventional ODNs. Furthermore, the mechanism by which 
scavenger receptors are regulating the internalization must be studied in greater details. It 
would be of great interest if one could identify specific receptor(s) that are engaging with 
dendrimeric ODN and perhaps in a more broader sense act as a cell-surface nanoparticle DNA 
recognition sensor. Planned experiments that will follow this thesis are to inhibit expression 
of possible scavenger receptor candidates (CXCL16, SRA, SRB, CD36, MARCO and etc.) 
via siRNA sequences and look the effects on dendrimer-mediated immune activation. After 
selecting possible target receptors, to further confirm our results we will use antibody 
mediated blockage of scavenger receptor. Third way is to transfect stably TLR9 expressing 
HEK cells with plasmids i) expressing scavenger receptor genes plus ii) a luciferase reporter 
gene.  
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Moreover, we would like to evaluate via confocal microscopy and FACS analyses which type 
of cells in human PBMC or mouse splenocytes primarily took up the dendrimeric CpG ODN, 
use of labelled-ODNs is very important during such analyses.  
We would like to also channel some of our efforts to study immunostimulatory potential of 
dendrimeric CpG ODN on human immune cells, PBMC or individual TLR9-expressing 
primary cells (pDCs and B-cells) and cell lines with an aim to test reproducibility our results 
on human immune cells. As our dendrimers are origined from optimum mouse-active 
sequences (PuPuCpGPyPy), we should also test dendrimers with human-active sequences 
(PuPyCpGPuPy). 
IFNα-inducing capability of CpG ODN is very unique feature of D-Type ODNs and is a 
pivotal cytokine during anti-viral and anti-cancer therapy. Although we showed IFNα 
induction by ODN420 on mRNA-level, we should demonstrate it on protein level. Recently, it 
was shown that multimerized phosphodiester sequences effectively induce IFNα from human 
dendritic cells, while CpG motif has additive effect on induction (Haas T, 2008a, 2008b). As 
ODN420 folds spontaneously into multimeric structures, we plan to investigate this 
possibility by synthesizing phosphodiester linked ODNs along with phosphorothioate 
counterparts and evaluate its IFNα induction ability by mouse and human immune cells. 
Moreover, it is very essential to synthesize TCGA core sequence using this approach that are 
used to generate central palindrome of D-type ODNs (please see section 1.2.1.1.) and 
compare them side by side. We aim also to search exact relationship between multimerization 
degree and immune-activating potential. For this different dendrimers can be designed such as 
3-stranded and more than 7-stranded forms. Size of individual molecule or molecular 
aggregate will be determined by AFM. There might be size-specific receptors on immune 
cells which will be checked for its role in recognition of nanoparticles with varying-size.  
Consequently, in vivo performance of these ODNs must be performed. Mice will be pretreated 
with DNA nanoparticles and challenged against pathogens to establish enhanced 
immunoprotective potential. The present data, strongly suggest that dendrimeric CpG ODNs 
could be utilized in immunotherapy against infectious diseases, in anti-allergic and anti-
cancer therapy, as well as a vaccine adjuvant improving the performance of already existing 
or novel vaccines.   
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8. APPENDICES 
8.1. Appendix I 
Buffers, Solutions, Culture media 
Blocking Buffer (ELISA) 
• 500 ml 1x PBS 
• 25 grams BSA (5%) 
• 250 µl Tween20 (0,025%) 
Crystal particles of BSA should be dissolved very well, with magnetic-heating stirrer for 
20-30 min. The buffer should be stored at -20°C. 
Loading Dye (Agarose gel) 
• 0,009 grams Bromofenol blue  
• 0,009 grams Xylen cyanol  
• 2,8 ml ddH2O 
• 1,2 ml 0,5M EDTA 
• 11 ml glycerol 
After preparing, just vortex it. 
PBS (Phosphate Buffered Saline) [10x] 
• 80 grams NaCl 
• 2 grams KCl 
• 8,01 grams Na2HPO4 . 2H2O 
• 2 grams KH2PO4 
complete into 1 lt with ddH2O (pH= 6,8).  
For 1X PBS’s pH should be ≈ 7,2-7,4 and should be autoclaved prior to use. 
TAE (Tris-Acetate-EDTA) [50x] 
• 242 grams Tris (C4H11NO3) 
• 37,2 grams Tritiplex 3 (EDTA= C10H14N2Na2O2 . 2H2O) 
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• 57,1 ml Glacial acetic acid 
completeinto 1 lt ddH2O 
Dissolves in ≈1 day. Should be autoclaved. Diluted to 1X prior to use 
T-cell Buffer [ELISA] 
• 500 ml 1x PBS 
• 25 ml FBS (5%) 
• 250 µl Tween20 (0,025%) 
The buffer should be stored at -20°C. 
Wash Buffer [ELISA] 
• 500 ml 10x PBS 
• 2,5 ml Tween20   
• 4,5 lt dH2O 
RPMI-1640 (Hyclone) 
• 2  % : 10 ml FBS (Oligo FBS = inactivated at 65°C, Regular FBS = inactivated at 
55°C ) 
• 5   % : 25 ml FBS 
• 10 % : 50 ml FBS 
• 5 ml Penicillin/Streptomycin (50 µg/ml final concentration from 10 mg/ml stock) 
• 5 ml HEPES (Biological Industries), (10 mM final concentration from 1M stock ) 
• 5 ml Na Pyruvate, (0,11 mg/ml final concentration from 100mM, 11 mg/ml stock) 
• 5 ml Non-Essential Amino Acids Solution, (diluted into 1x from 100x concentrate 
stock) 
• 5 ml L-Glutamine, (2 mM final concentration from 200 mM, 29.2 mg/ml stock) 
In 500 ml media 
8.2. Appendix II  
TLR expression profile upon treatment of murine splenocytes with CpG ODN. 
 After 1h and 6h stimulation with CpG ODNs (indicated on figures) and controls (data not 
shown), cells were checked for expression of tlr1 (A), tlr2 (B), tlr3 (C), tlr4 (D), tlr5 (E), tlr6 
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(F), tlr7 (G) and tlr9 (H) by using PCR. Agarose gel band intensities of indicated genes and 
housekeeping gene (b-actin) were measured. tlr/β-actin ratios were calculated. 
A) 
 
B) 
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C) 
 
D) 
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E) 
 
 
F) 
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G) 
 
H) 
 
8.3. Appendix III  
Cytokine & chemokine expression profile upon treatment of murine splenocytes with 
CpG ODN. After 1h and 6h stimulation with CpG ODNs (indicated on figures) and controls 
(data not shown), cells were checked for expression of  il-1b (A), tnfα (B), il-6 (C), il-15 (D), 
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il-18 (E), ifnα (F), ifnγ (G), ip10 (H), mip-1α (I), mip-1β (J), mcp-1 (K), cxcl16 (L)  by using 
PCR. Agarose gel band intensities of indicated genes and housekeeping gene (β-actin) were 
measured. Cytokine(chemokine)/β-actin ratio was calculated. 
A) 
 
B) 
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C) 
 
D) 
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E) 
 
F) 
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G) 
 
H) 
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J) 
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K) 
 
L) 
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8.4. Appendix IV 
Dendrimer interference with PCR.  
In vitro stimulation experiments showed that RNA, or cDNA from the same RNA, of 
bifunctional dendrimer treated samples were inhibited somehow to display bands indicating 
gene expression (A). We assumed that dendrimer stays in cellular extracts due to their highly 
stable structures (please see table 4.2.) and comes with isolated RNA. Then either inhibits 
cDNA synthesis or PCR from cDNA. Next experiments showed that latter was the case. Since 
cDNA obtained from dendrimeric ODN treated samples gave smear on gel which was 
indifferent from other working samples and dendrimeric ODN addition to RNA of 
conventional ODN treated samples didn’t inhibit cDNA synthesis (B). While, even 1 µg 
dendrimeric ODN addition to cDNA samples blocked PCR of otherwise working sample. 
Linear ODN or trifunctional dendrimeric ODN addition to cDNA samples were not effective 
as bifunctional dendrimer to inhibit PCR (C).  
β-actin
IP10
CXCL16
A)
B)
C)
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8.4. Appendix IV 
ODN422 were susceptible to DNAse treatment, unlike ODN420. ODN420, 421 and 422 
were subjected to 30min  DNAse I treatment and analyzed with PAGE subsequently.  
 
 
